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SUMMARY
This dissertation is concerned with (1) the identifica¬
tion of surface membrane markers for immunoglobulin G and
complement on human eosinophils; (2) how certain pharmaco¬
logical mediators, which stimulate eosinophil locomotion,
influence the expression of these receptors; and (3) the
susceptibility of schistosomula coated with antibody and/or
complement to killing by human eosinophils, neutrophils and
mononuclear leucocytes.
By the rosette technique and immunofluorescence it
was shown that human eosinophils and neutrophils bear
membrane receptors for rabbit and human IgG and the human
complement components, C3b, C3d and C4. There was a
significantly reduced percentage of eosinophils bearing
receptors for C4 and C3b when patients with eosinophilia
of various aetiology were compared to controls. However,
no differences were found with IgG receptors.
The ECF-A tetrapeptides (Val-Gly-Ser-Glu and Ala-Gly-
Ser-Glu) and histamine, agents previously shown to be
preferentially chemotactic for the eosinophil, markedly
enhanced the expression of human eosinophil receptors for
C3b. The enhancement appeared to be highly selective for
the eosinophil since there was no evidence that C3b
receptors on neutrophils or monocytes were altered by these
pharmacological agents. The mediators similarly enhanced
receptors for C4 but under the same conditions C3d and IgG
(Fc) receptors were unaffected. A number of other pharmaco¬
logical mediators including bradykinin and the prostaglandins
PGE^, Eg and Fga, had no apparent effect on eosinophil C3b
receptors. However, a major histamine catabolite, imidazole-
acetic acid, also recognised as an anaphylaxis-associated
eosinophilotactic agent, enhanced eosinophil C3b receptors
to a degree comparable to that of histamine.
These results suggested that pharmacological mediators
of hypersensitivity may regulate certain eosinophil dependent
biological reactions and that there may be a direct relation¬
ship between the cell surface 'recognition unit1 for
eosinophil locomotion and some of the membrane receptors
which promote the adhesion of eosinophils to opsonized
particles.
Studies were also undertaken to determine the suscepti¬
bility of schistosomula coated with antibody (Ab) and/or
complement (c), to destruction by human eosinophils,
neutrophils and mononuclear leucocytes. It was shown that
(1) damage to schistosomula in vitro can be mediated by human
eosinophils, neutrophils or mononuclear leucocytes in the
presence of either 'Ab alone', 'C alone' or 'Ab + C'; (2) the
efficiencies of the three experimental systems were Ab + C >
C > Ab irrespective of whether effector cells were granulocytes
or mononuclear leucocytes; and (3) preferential killing of
schistosomula by the human eosinophil, as compared to the
neutrophil, was not demonstrable with Ab alone but only when
complement was present either alone or in combination with
antibody.
These studies indicate that the regulation of various
eosinophil-associated biological events may be dependent on
surface membrane markers, especially those for complement.
GENERAL INTRODUCTION
In this thesis experiments concerned with the detection
of immunoglobulin and complement receptors on the human
eosinophil leucocyte membrane and the pharmacological
modulation of their expression, particularly by specific
eosinophilotactic agents, are described. In addition,
the role that human eosinophils may act as killer cells
against the larval stage (schistosomula) of Schistosoma
mansoni through the presence of their immunoglobulin and
complement receptors is evaluated.
As an introduction a brief review of the vast
literature relating both to the eosinophil leucocyte and
receptors for immunoglobulin and complement on various
cell types will be given.
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Probably the first description of the eosinophil
leucocyte was that of Wharton Jones (1848) who described
the presence of 'coarse granular cells' in the blood of
several species including man, but it was not until 1865
that the cell was recognized by Schultze as a distinct
entity and given a morphological description. In 1879
Ehrlich observed that the granules had a greater affinity
for eosin dyes and he was the first to coin the name
'eosinophil*. Since that time the eosinophil leucocyte
has remained a continuous source of interest for many
workers and even as early as 1914, when Schwarz summarized
the current literature on the eosinophil, he was able to
quote 2,758 references.
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2.0 THE STRUCTURE OF THE EOSINOPHIL LEUCOCYTE
The human eosinophil is a granulocyte 12-17 pm in
diameter with a bilobed and sometimes trilobed nucleus
(Zucker-Franklin, 1968) containing the characteristic large
retractile granules which stain bright orange with eosin dye.
2.1 The eosinophil nucleus
The nucleus of the eosinophil has lobular configuration
in man and an annular one in the mouse and rat. It contains
clumps of condensed chromatin distributed against the
nuclear membrane with filamentous connections between the
nuclear lobes (Zucker-Franklin, 1968). The eosinophil nuclei,
like those of other mature granulocytes, do not contain a
nucleolus suggesting that major biosynthetic nuclear processes
have ceased in the mature cells.
2.2 The eosinophil granule
The large refractile intracytoplasmic granules have a
unique structure which many investigators believe may point
to an understanding of specialised functions of the cell.
They measure 0.5-1.5 pm in their longer diameter and 0.3-1.0 pm
in their shorter diameter (Zucker-Franklin, 1968). They have
a relatively high density of 1.24 grams/millilitre (West et al,
1975). By ultrastructural studies they were shown to be
biconvex discs bound by a double-layer membrane and to contain
an electron-dense crystalline-like core in the centre
parallel to the long axis of the granule (Grey and Biesele,
1955). The central core is surrounded by a less electron-
dense matrix. Reversal of electron density pattern of the
core and matrix was observed among the granules of an
individual eosinophil obtained from a patient with
eosinophilia (Zucker-Franklin, 1974). Earlier workers
made similar observations (Ghadially and Parry, 1965) and
they have postulated that heterogeneity of the granules may
be related to various functions. The granular core is
relatively resistant to mechanical trauma and osmotic lysis
and was shown to have a high phospholipid content and to
contain a major basic protein rich in arginine (Vercauteren,
1950). Miller et al (1966) reported that the crystalline
core which appears as parallel lines with regular spacing
is a cubic lattice with sides measuring about 30 A in
rodents and 40 A in man. The core is probably responsible
for the formation of the Charcot-Leyden crystals apparent
whenever massive disintegration of the eosinophil occurs,
e.g. in the sputum of patients with allergic asthma (Welsh,
1959).
Mature or *later eosinophils contain a second type of
smaller granule measuring about 0.1-0.5 |im in diameter.
These granules are round, homogenous and do not contain a
central core. They contain most of the arylsulphatase and
acid phosphatase activity associated with the cell (Parmley
and Spicer, 1974).
2.3 The eosinophil cytoplasm
The structure of the eosinophil cytoplasm differs
from that of other mature granulocytes in containing more
numerous mitochondria, a better developed Golgi zone
(Goodman et al, 1957) and the presence of free ribosomes
and rough endoplasmic reticulum (Hirsch, 1965). These
differences are compatible with the more active metabolic
7
state of the eosinophil.
2.4 The eosinophil cell membrane
Morphologically the eosinophil cell membrane is
similar to that of the neutrophil and lymphocyte. Scanning
electron microscopic studies have shown that most eosinophils
are spherical with some microvilli. Certain cells show
membrane deformations such as ridge-like profiles,
'ruffles* or 'blebs* (Polliack and Douglas, 1975). The
cell membrane of the eosinophil differs from that of the
neutrophil by being more resistant to changes in osmolarity
and solvents such as acetone. This property is useful as
it forms the basis for one method of direct eosinophil
counting (Discombe, 1946; Speirs, 1952).
2.5 The eosinophil antigens
The eosinophil appears to be antigenically distinct
from other mature granulocytes. Recent demonstrations
that mature eosinophils bear certain cell-specific antigens
made it possible to produce specific antisera against these
eosinophil antigens. Mahmoud et ajL (1973), by immunising
rabbits with mouse peritoneal eosinophils and absorbing the
serum obtained with other leucocytes, produced a highly
specific rabbit anti-mouse eosinophil serum. Later, these
same workers produced a monospecific rabbit anti-human
eosinophil serum (Mahmoud et al, 1974). Gleich ej; al (1975) could
prepare rabbit anti-guinea pig eosinophil serum; they
showed, however, that although neutrophils were not directly
affected by this anti-eosinophil serum, these cells could
absorb out the anti-eosinophil activity. Therefore, it
8
was concluded that similar antigens were present on both
cell types, but in quantitatively greater amounts on the
eosinophil.
Other components within the eosinophil also show a
degree of cell or species specificity. For example, the
major basic protein is antigenically different in the
guinea pig and man (Lewis et ad, 1976), whilst eosinophil
peroxidase can be distinguished from the neutrophil myelo¬




3.0 HISTOCHEMICAL STUDIES AND ENZYME ANALYSIS
A number of enzymes are released following the
disruption of the eosinophil granules (Archer and Hirsch,
1963). These include acid-phosphatase, (3-glucuronidase,
acid (3-glycerophosphatase, ribonuclease, arylsulphatase,
phospholipase and cathepsin.
3.1 Peroxidase
The eosinophil granules contain a peroxidase which is
easily recognised histochemically and which remains bound
to the insoluble granule residue following disruption.
However, recent histochemical and electron microscopic
studies have shown that the peroxidase exists mainly in the
small homogenous granules and the matrix of the specific
granules of rats (Yamada and Yamauchi, 1966), rabbit
(Bainton and Farquhar, 1967), guinea pig (Cotran and Litt,
1969) and man (Enomoto and Kitani, 1966). Eosinophil
peroxidase differs both chemically and antigenically from
the myeloperoxidase of the neutrophil and does not appear
to participate in the peroxidase-hydrogen peroxide-halide
bactericidal system (Bujak and Root, 1974).
3.2 Arylsulphatase
Arylsulphatase was first identified histochemically
within eosinophils, neutrophils and megakaryocytes by
Austin and Bischel in 1961. A year later Tanaka et al (1962)
showed that the eosinophil contained the highest amounts of
arylsulphatase activity in human leucocytes followed by
basophils and neutrophils in the ratio of 8:2:1 respectively.
These workers also suggested that any disease process which
10
induces an eosinophilia will consequently give rise to
greatly enhanced blood arylsulphatase levels. Eosinophil
arylsulphatase was found to inactivate slow reacting
substance of anaphylaxis (SRS-A) jln vitro in a dose- and time-
dependent fashion (Wassermann et al, 1975) and also the
eosinophil chemotactic factor of anaphylaxis (ECF-A) (Bach
et al, 1975); both recognised as mediators of immediate
hypersensitivity reactions. These effects suggest that
eosinophil arylsulphatase may play an important role in
modulating hypersensitivity reactions.
3.3 The eosinophil major basic protein
About half the granule content of protein consists of
a basic material which is insoluble at physiological pH and
binds firmly to acid alanine dyes, possibly explaining the
characteristic eosinophilic staining of the cells (Behrens
and Marti, 1962). Gleich et al (1973) and Gleich ejt al (1974)
have purified the major basic protein from guinea pigs, rats
and human eosinophils. This basic protein accounted for
approximately 55% of the total granule protein, had a
molecular weight of 11,000 and had a high content of arginine.
Examination of the major basic protein for the possible
biological activities revealed no peroxidase activity and
weak, if any, antihistaminic activity. In contrast to the
neutrophil granule basic proteins, the eosinophil major basic
protein did not increase vascular permeability or contract
the guinea pig ileum, and had little bactericidal activity
against a variety of bacterial strains tested. However,
it was shown to neutralise heparin to a degree comparable
/
to that of protamine. The major basic protein may be
responsible for the characteristic properties of radio-
opacity (Harris et al, 1961) and autofluorescence (Fuerst
and Janach, 1965) of the eosinophil leucocyte.
3.4 Phospholipase
Although phospholipase activity can be demonstrated
histochemically in the eosinophil granules (Ottolenghi et al.
1967), the data concerning the type of phospholipase are
somewhat conflicting at the present time. However, Kater
et al (1976) have reported the presence of phospholipase D
activity in human eosinophils. Interestingly this enzyme
which is common in plants has rarely been identified in a
mammalian tissue.
Other enzymes were also described in the eosinophil
leucocyte, e.g. plasminogen (Barnhart and Riddle, 1965;
Barnhart, 1968) and both kinin-producing and kininase
activities (Melmon and Cline, 1967; Melmon and Cline, 1968).
3.5 Prostaglandins
Prostaglandins and E2 may be released by the
eosinophil during an allergic reaction. Hubscher (1975a, b)
has demonstrated the release of a material, termed the
eosinophil derived inhibitor (EDI), from eosinophil-rich
fractions separated from the peripheral blood of atopic
individuals. This material, which was characterised as a
prostaglandin, was shown to inhibit the release of histamine
by basophils. Hubscher (1975a, b) proposed that significant
amounts of prostaglandins, originating from human leucocytes,
were synthesized by the eosinophil and that these cells may
modulate the allergic response by inhibiting basophil
degranulation as a result of local prostaglandin release.
3.6 Trace elements
Eosinophils contain relatively high concentrations of
copper as well as other trace elements including zinc,
cobalt, magnesium and manganese (McNary, 1960). The
presence of zinc may be of importance since it is known to
inhibit histamine release from mast cells (Kazimierczak and
Maslinski, 1974), to prevent platelet aggregation and their
release of serotonin (Chvapi et al, 1975) and to inhibit
macrophage migration, phagocytosis and the subsequent
metabolic response (Karl et al, 1973).
4.0 OXIDATIVE METABOLISM
The few reports on eosinophil oxidative metabolism
suggest that the cell resembles the neutrophil in terms of
the metabolic burst accompanying contact with opsonised
particles and phagocytes. Although the large and well-
developed mitochondria suggest an aerobic mechanism for
energy production, there is some evidence suggesting the
possibility of an anaerobic metabolic pathway. Thus, of
the glucose utilized by the cell, about 90% is converted
to lactic acid while only 10% is oxidized to COg or used
for glycogen, amino acid or lipid synthesis (Stjernholm
et al, 1969).
In all studies where the oxidative metabolic activities
of the eosinophil were compared with those of the neutrophil,
it was shown that the resting and the stimulated eosinophil
has a higher metabolic activity. In these studies several
metabolic variables were tested, e.g. hexose monophosphate
shunt, Krebss cycle and hydrogen peroxide production. The
greater oxidative response in the eosinophil was shown to
be primarily due to increased activity of nicotinamide-
adenine dinucleotide phosphate-H oxidase (NADPH-oxidase)
of granular origin rather than soluble NADPH-oxidase which
is the enzyme known to operate in the neutrophil (Baehner
and Johnston, 1971).
However, in spite of the greater ability of the
eosinophil to generate HgOg, these cells were found to be
less efficient in terms of bactericidal ability, i.e. they
are less capable of efficiently utilizing the peroxidase-
hydrogen peroxide bactericidal system known to participate in
intracellular killing of ingested organisms by the neutrophil.
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5.° ORIGIN, KINETICS AND DISTRIBUTION OF THE EOSINOPHIL
It was shown in the rat that, before birth, eosinophil
production occurs both in the thymus and lymph nodes
(Ryt&maa, 1960); whereas in the adult most of the eosinophils
are produced in the bone marrow (Ringoen, 1938). The exact
precursor of the eosinophil in the bone marrow has not yet
been identified with certainty. However, it is believed
that the cell arises together with other granulocytes from
a multipotential stem cell and proceeds through several
stages before entering the bloodstream as a mature eosinophil.
Studies on the kinetics of the rat eosinophil showed
that the cell cycle time is 30 hr in normal rats and 9 hr in
animals stimulated with Trichinella spiralis (Spry, 1971a).
In the same report it was also calculated that the total bone
marrow eosinophil transit time was 5.5 days in unstimulated
rats as compared to 3.6 days in parasite-stimulated animals.
The eosinophil transit time in the blood has been found to
be relatively short in comparison with other cells. The
blood half life was shown to be \ hr in the dog (Carper and
Hoffman, 1966), 6-10 hr in the rat (Spry, 1971b) and 4.5-5 hr
in man (Herion et al, 1970). More recently Dale et al (1976)
studied six patients with hypereosinophilia by isolating their
51
eosinophils, labelling them with Cr, reinjecting them and
measuring the eosinophil specific activity at various
intervals. Initially the radioactivity attributed to the
eosinophils declined rapidly within the first 3 hr, but it
subsequently increased, peaking at 6-24 hr. Thereafter
the radiolabelled eosinophils were removed exponentially
from the circulation with a half life of 44 hr. / Similar
findings were previously reported by Herion et al (1970) and
Greenberg and Chikkappa (1971). These observations are very
suggestive of eosinophil recirculation.
The tissue life span of the rat eosinophil was calculated
as 2-4 days (Cohen et al, 1967) and they are known to be end
cells incapable of division (Hirsch, 1965).
Blood eosinophils are probably in transit from the
bone marrow to their definitive tissue sites (Hudson, 1962;
Archer, 1963). In normal individuals the eosinophil
comprises between 1-5% of the total circulating white cell
population and an absolute count of greater than 240 cells/
cu.mm is considered abnormal in man (Discombe, 1946).
However, several physiological factors may influence
circulating eosinophil levels such as diurnal variations
(Rytttmaa, 1960), the state of nutrition (Opie, 1904) and
oxygen tension (Hudson et al, 1967). Rat eosinophils are
normally seen in various tissue sites including the skin,
lungs, liver, bone marrow, spleen, uterus, vagina and gastro¬
intestinal tract (Ryt&maa, 1960). It was shown that for
every circulating eosinophil there are about 200 mature cells
in the bone marrow reserve and about 500 in the loose sub¬
mucosal connective tissues. Therefore, it seems that there
is a continuous turnover of eosinophils, with production and
maintenance of a reserve pool in the bone marrow and transport
via the blood to certain tissue sites. The fate of the
eosinophil is not yet clear in either normal or eosinophilic
patients, but damaged cells may either be phagocytosed by
macrophages or they may be excreted by passage through the
gastro-intestinal and respiratory tracts. /
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B. RECEPTORS FOR COMPLEMENT AND IMMUNOGLOBULINS
The presence of membrane surface receptors for the Fc
portion of specific immunoglobulins and certain complement
components on a variety of human and animal cells has been
described by various workers. These receptors appear to
be an integral part of membrane recognition systems through which
the cell may respond to various environmental stimuli.
A brief summary of work on both Fc and complement
receptors will be given in this chapter to serve as a
background for the experiments which are described in
subsequent chapters.
1.0 RECEPTORS FOR IMMUNOGLOBULINS - 'Fc RECEPTORS'
Although the presence of receptors which can recognise
a certain region within the immunoglobulin molecules on
certain cell types has been recognised since 1966 by Uhr and
Phillips, the term *Fc receptor* was first introduced by
Paraskevas et al (1972) to describe in distinct molecular
entity, present in the cell membrane, which can recognise
and react with some region within the Fc portion of certain
immunoglobulin classes. In this context Fc receptors were
described on various human and animal cell types. They
were described on macrophages (Howard and Benacerraf, 1966),
monocytes (Huber and Fudenberg, 1968), neutrophils (Lay and
Nussenzweig, 1968), platelets (Henson, 1969), mast cells
(Tigelaar et al, 1971), B lymphocytes (Basten et aT, 1972;
Paraskevas et al, 1972), activated T lymphocytes (Yoshida and
Anderson, 1972), various malignant cell populations including
lymphomas and leukaemias (Grey et al, 1972; Shevach et al, 1972;
Jondal and Klein, 1973). More recently Fc receptors were
also described on human yolk sac and placental membrane
(Moskalewski et al, 1975; Matre et al, 1975).
Although all the Fc receptors on various cell types
are operationally similar in that they show marked affinity
for sites in the Fc region of certain immunoglobulin classes,
the phenomenon has various biological implications. For
example, on mast cells and basophils the Fc receptors show
high affinity for IgE of the same or very closely related
species. Similarly, macrophages have high affinity
receptors for IgG. Thus the Fc receptors on these cell
types will bind to the immunoglobulins even in the absence
of an antigen. In contrast, the receptors for IgG on
neutrophils, B lymphocytes and platelets are known to be of
low affinity and in these cell types it is, therefore,
essential that the Fc region is present in the form of an
antigen-antibody complex to allow a stable binding to the
receptor. Other differences also occur between Fc receptors
on various cell types. For example, although it is now
agreed that most Fc receptors will bind to specific sites on
the cXj domain of the Fc region, recent studies on the Fc
receptors of human placental tissue and of some *K-cells*
suggest that both CX2 and CX^ domains may be involved
(Yasmeen et al, 1973; Yasmeen et al, 1976).
The reaction between Fc receptor-bearing cells and the
Fc portion of the immunoglobulin in the indicator system is
considerably stabilised by procedures which alter the
conformational structure of the Fc portion, i.e. involvement
of the molecule in an antigen-antibody complex formation or
chemical or heat aggregation of the immunoglobulin molecule.
Therefore, all techniques used to demonstrate the presence
of the Fc receptors have involved the activation of the Fc
region leading to conformational changes to facilitate the
interactions with the Fc receptor. The most commonly used
techniques to detect these receptors on various cell types
are:
(a) The Rosette Technique - where erythrocytes are
sensitized with a sub-agglutinating titre of IgG (or any
other antibody class) preparation with specificity for the
erythrocyte antigen. When the sensitized erythrocytes are
incubated with the Fc receptor-bearing cell at the optimal
conditions clusters are formed in which the receptor-bearing
cell is either partially or totally surrounded by red cells.
These clusters are usually termed EA *erythrocyte-antibody*
rosettes.
(b) Immunofluorescence - where the immunoglobulin molecule
is aggregated either by heat or by chemical agents. The
aggregated immunoglobulin is then incubated with the receptor-
bearing cells under optimal conditions and binding can be
detected by using fluorescent labelled anti-immunoglobulin.
(c) Autoradiography - where the immunoglobulin molecule
is labelled with radioactive iodine and either heat aggregated
or combined to a specific antigen to form a radioactive antigen
antibody complex, which is then incubated with the target
cells and the preparation can be examined autoradiographically
to assess the amount of radioactive uptake.
1.1 Specificity of Fc receptors
Apart from the receptor for IgE on mast cells and
basophils, most reports on Fc receptors on various cell
types refer to IgG. However, receptors for other immuno¬
globulins have recently been reported. Capron et al (1975)
described the killing of schistosomula of Schistosoma mansoni
by rat macrophages in an IgE-dependent system indicating the
presence of a receptor for the Fc portion of the IgE class
on macrophages. Also Gonzalez-Molina et aJ (1977) described
the presence of a receptor for the Fc region of IgE on a sub-
population of normal human peripheral B lymphocytes. Over
the last few years the presence of a receptor for IgM on
certain subpopulations of human T and B lymphocytes has also
been reported by various workers. Moretta et al (1975)
described the presence of IgM receptors on normal human T
lymphocytes. This finding was confirmed by McConnell and
Hurd (1976) and by Gmelig-Meyling et al (1976). Ferrarini
et al (1976) confirmed these observations and showed that
the receptor is specific for the Fc portion of IgM. Later
Pichler and Knapp (1977) described the presence of a similar
receptor on chronic lymphatic leukaemia cells and suggested
that this receptor may be a unique property to neoplastic
cells since they were unable to detect it on normal B
lymphocytes. However, this assertion was not supported by
Ferrarini et al (1977) who demonstrated the presence of IgM
receptors on normal human B lymphocytes after overnight
culture in an IgM-free medium.
1.2 Physiochemical characterization of Fc receptors
Several investigators have attempted to characterize
Fc receptors chemically. One approach has been the use of
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enzymes of known substrate specificity. Using this technique
Davey and Asherson (1967) showed that Fc receptors on guinea
pig and rabbit macrophages were resistant to trypsin,
chymotrypsin and papain. In fact, several other studies
suggested that enzyme treated cells may have a greater
affinity to bind antibody than untreated control cells (Arend
and Mannik, 1973). However, the same Fc receptors which
were found to be resistant to proteolytic enzymes were shown
to be susceptible to phospholipase. This does not necessarily
imply that they are phospholipid in nature since any perturba¬
tion of the fluid bilayer may alter the activity of the
constituent membrane proteins. On the other hand, Unkeless
and Eisen (1975) have found that the Fc receptor activity of
mouse macrophages was lost following a 15 min incubation with
trypsin. However, about 60% of the binding activity was
restored when the trypsin treated cells were incubated for
12 hr in serum-free medium. More recently, Anderson and
Grey (1977) have assayed detergent cell lysates and culture
supernatant fluid of mouse cells for the presence of soluble
Fc receptors by means of a radiological bioassay. In this
study the soluble Fc receptors of all cells tested, except
mouse macrophages, behaved as lipoprotein. In the absence
of detergent these Fc receptors sedimented as a 20 S macro-
molecule and as a 7-9 S material in the presence of a detergent.
Therefore, in spite of the rapid development of techniques
for isolation and characterization of membrane associated
molecules, there remains a considerable controversy concerning
the exact physiochemical nature of Fc receptors.
1.3 Biological functions of Fc receptors
The presence of Fc receptors on a variety of cell types
was shown to be a basic requirement for their mediation
of several important immunological processes. Some of
these processes are reviewed in the following paragraphs.
(i) Phagocytosis
This is one of the major immunological processes in
which the participation of Fc receptors is thought to be a
vital factor. For the neutrophil it was shown that the
IgG coating of sheep red blood cells or S. aureus is an
important prerequisite for triggering the internalisation
phase of phagocytosis. It is also known that the adherence
of the IgG coated particle to the phagocytic cell through its
Fc receptor may be the first step towards the completion of
the process of phagocytosis.
For the monocyte the presence of the Fc receptor is
also important for phagocytosis. However, unlike the
neutrophil, the monocyte can ingest target cells without
being coated with antibody, i.e. the recognition of an
antibody is not an absolute requirement for phagocytosis.
There are certainly some other recognition mechanisms
whereby the monocyte can recognise the particle as foreign.
Although the antibody is not an obligatory requirement for
the phagocytosis by monocytes, its presence can greatly
enhance the process, presumably by causing close contact
between the cell and antibody-coated particle.
(ii) Antibody-dependent cell-mediated cytotoxicity (K-cell
cytotoxicity)
In the original description of the killer cell (K-cell)
system the effector cells are identified as normal ^on-
sensitized non-adherent mononuclear cells which had neither
B-cell nor T-cell characteristics and they were, therefore,
thought to belong to the *null* cell subpopulation of
lymphocytes. However, when this phenomenon was studied
more closely it became apparent that other cell types
including macrophages and polymorphonuclear cells can act
as K-cells against various antibody coated target cells.
All cells capable of mediating K-cell cytotoxicity are
known to bear Fc receptors. The involvement of the Fc
receptors was clearly demonstrated by the finding that
antibody-dependent damage of target cells can be completely
inhibited by blockade of these receptors following the
incubation of the effector cells with antigen-antibody
complexes. The role that the Fc receptor may play in the
induction of the K-cell lysis may either be:
(a) A passive role - whereby the Fc receptor may serve to
concentrate the antibody coated target particles in the
vicinity of the K-cell and hence facilitating contact
between the membranes of the target and the effector
cells. The lysis of the target cell may then occur as
a result of the action of a membrane-bound effector molecule
(a protease or a phospholipase) or the release of a soluble
mediator.
(b) An active role - whereby the occupation of the Fc
receptor may actively trigger the release and activation of
certain effector molecules via a second messenger, e.g.
cyclic GMP.
At the moment the precise role of Fc receptors in
the K-cell phenomenon is not clear and until the whole
molecular mechanism of K-cell lysis is clarified, the role
of Fc receptors in antibody-dependent damage of target cells
remains speculative.
(iii) Secretion
The role that Fc receptors may play in inducing the
secretion of certain enzymes is best discussed in relation
to the macrophage. This cell is known to be a secretory
cell for a variety of macromolecular products, e.g. lysozyme
and several neutral proteases. Lysozyme is secreted
continuously by the macrophage whereas the other enzymes are
secreted in association with the stimulation of the cell and
with phagocytosis. The involvement of Fc receptors in the
secretion process stimulated by antigen-antibody complexes
or heat aggregated IgG is probably similar to their
involvement in phagocytosis.
The role of Fc receptors on the polymorphonuclear cells
in inducing secretion of lysozomal enzymes is thought to be
similar to their role in the macrophage.
(iv) The role of Fc receptors on lymphocytes
The presence of Fc receptors for IgG and IgM on various
lymphocyte subpopulations will allow these cells to react
with immune complexes. The interaction of immune complexes
with lymphocytes through their Fc receptors has been shown
to induce a variety of important immunological phenomena,
including immune regulation by feedback suppression of
antibody formation (Sinclair and Chan, 1971), immunological
tolerance (Diener and Feldmann, 1970) and immunological enhance
ment (Sjogren et al, 1971; Baldwin et al, 1972) (reviewed by
Kerbel and Davies, 1974).
2.0 COMPLEMENT RECEPTORS
The first indication of the presence of membrane
receptors for altered complement components on certain
mammalian cells was the demonstration of the adherence
reaction between trypanosomes and human erythrocytes in the
presence of fresh immune serum (Duke and Wallace, 1930).
The adherence of bound C3 to receptors on primate erythrocytes
was originally called 'immune adherenceJ (Nelson, 1953).
Subsequently it became apparent that complement receptors
had a widespread distribution among various haemopoietic
cells. Thus apart from C3b receptors, receptors for Clq,
C4 and C3d have also been described.
2.1 Clq receptors
The presence of this receptor was reported on both
T and B lymphocytes (Dickler and Kunkel, 1972) and on certain
lymphoblastoid cells (Bokisch and Sobel, 1974). At present
the biological significance of this receptor is not clear
although the release of vaso-active amines by platelets
(which may also have a receptor for Clq) can be inhibited
by Clq (Suba and Csako, 1976).
2.2 C4b receptors
The occurrence of C4b receptors on human erythrocytes
and C4b dependent immune adherence was first described by
Cooper (1969). The C4b receptor was shown to react with
both cell bound and fluid phase C4b. Later, Bokisch and
Sobel (1974) described the presence of a C4b receptor on
human B lymphocytes and lymphoblastoid cells. At the same
time Ross and Polley (1974) independently demonstrated the
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occurrence of C4b receptors on human granulocytes and
lymphocytes.
The relationship between the C4b and C3d receptors
on human B lymphocytes was evaluated by Bokisch and Sobel
(1974) and also by Ross and Polley (1975). Results from
inhibitory experiments by both groups favoured the idea that
human B lymphocytes have only one receptor for C3b and C4b.
However, in experiments performed with several human lympho-
blastoid cell lines (Bokisch and Sobel, 1974) evidence was
provided for a C3b receptor distinct from the C4b receptor.
Recent immunochemical studies revealed a striking similarity
between C3 and C4. In the course of complement activation
C3 and C4 are cleaved by the enzymes, C3 convertase and CI
esterase respectively, into a low molecular weight 'a®
fragment and a large molecular weight !b' fragment. Upon
cleavage C3b and C4b require two binding sites, a labile
binding site which allows the molecules to be attached to
cell membrane surfaces, antigen-antibody complexes and other
particles, and a stable binding site which enables both C3b
and C4b to react with C3b or C4b receptors on the surface of
various cells. Both molecules are susceptible to the enzyme
C3b inactivator (KAF) and so both molecules are rendered
•immune adherence* negative with human erythrocytes.
It is possible that the function of the C4b receptor
on phagocytic cells may be in the attachment of antigen-
antibody complexes to appropriate cells and hence phagocytosis
can be 1triggered*. The reduced clearance of immune complexes
in C4-deficient guinea pigs as compared to normal animals may
demonstrate the contribution of the C4b receptor on phagocytic
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cells to this mechanism. Ross and Polley 0-974) have shown
that relatively small amounts of C4 were needed for rosette
formation with human neutrophils compared with monocytes.
This bound C4 greatly enhances the phagocytosis of sheep
red blood cells sensitized with IgG by the human neutrophil.
The same workers have also suggested that the C4b receptor
activity may be more significant than that of the C3b
receptor in vivo, since complex-bound C4, but not bound C3b,
is protected from the action of C3b inactivator by the
presence of C2 (Cooper, 1975).
2.3 C3b receptors
The demonstration of the phenomenon of immune adherence
(Nelson, 1953) of C3 coated particles to human erythrocytes
was the first indication that there is a receptor on certain
cell types that is capable of binding the activated third
component of complement (C3b). Subsequently this receptor
was shown to be widely distributed among both human and
animal cells. For example, it was shown to be present on
the surface membrane of primate red cells, platelets,
macrophages, monocytes, polymorphonuclear leucocytes, T and
B lymphocytes, lymphoblastoid cells and glomerular epithelial
cells.
These receptors for C3b represent one of the most
important ways through which the complement system may be
involved in various immunological tissue reactions, since
it is known that the activation of the C3 molecule by either
the classical pathway C3 convertase or by the alternate




2.3 (a) Physiochemical characterization of C3b receptors
Several workers, using different techniques, have
attempted to characterize chemically the C3b receptors.
The expression of the C3b receptor on human erythrocytes,
lymphocytes and cultured lymphoblastoid cells is sensitive
to the enzyme, trypsin, and reducing agents such as
dithiothreitol, 2-mercaptoethanol, 2-amino-ethylisothiouronium
bromide hydrobromide (AET), reduced glutathione and L-cysteine
(Deirich et aJ, 1974a). The sensitivity of the C3b receptor
to these agents was shown to be temperature, time, dose and
pH dependent. Raji cells which had lost their C3b receptor
activity due to AET treatment will re-express this receptor
function after a lag period of 8-10 hr. It was concluded,
from these findings, that the C3b receptor is a protein-like
structure requiring disulphide bridges for the expression of
biological activity.
In 1975 Dierich ej: al were able to isolate C3b receptor
carrying plasma membrane fragments and partially characterized
them chemically. The membrane fragments, which were
solubilized using detergents, were completely inactive,
whereas the C3b receptor activity was still detectable on
membrane fragments which were extracted by potassium bromide.
Henson and Neshyba (1976) similarly solubilized platelet
membranes in detergents. When this material was fractionated
and the individual fractions were tested for inhibition of
histamine release from platelets using C3b coated zymosan
particles, the inhibitory activity was detected in a number
of fractions representing different molecular weights.
However, an inhibitory fraction of molecular weight
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30-40 x 10 daltons was consistently found and this fraction
could also bind to C3b coated zymosan particles.
2.3 (b) Biological functions of C3b receptors
The biological functions attributed to the C3b receptor
may best be discussed in relation to the individual cell
types.
(i) C3b receptors on phagocytic cells
The adherence of complement coated micro-organisms to
phagocytic cells is considered to be one of the most
important biological functions of the complement system.
Thus protection against various micro-organisms is
dependent on their opsonization by antibody and C3 and the
presence of C3b receptors on the phagocytic cell. The role
of complement, and in particular C3, in this respect was
clearly demonstrated by the finding that patients with
hereditary C3 deficiency suffer from repeated infection
although they have normal levels of immunoglobulins and can
form- antibodies to both thymus dependent and independent
antigens. For some time the opsonizing role that C3 may
have on various particles was unclear, especially with
regard to the part of the C3 molecule involved and the
relation between the C3b and Fc receptors on phagocytic
cells in initiating the adherence stage prior to the
subsequent ingestion. While investigating the functional
roles of IgG and C3b in phagocytosis by human neutrophils,
Scribner and Fahrney (1976) were able to show that phagocytosis
of S. aureus in the presence of heat inactivated serum was
severely depressed. They also showed that, in experiments
where the particle:neutrophil ratios were varied, the
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particle bound C3b could mediate a ten-fold enhancement of
the overall phagocytic rate. Also using quantitative data
regarding IgG sensitization they were able to show that
bound C3b can result in at least a three-fold decrease in
the amount of sensitizing IgG needed for 50% maximal
neutrophil phagocytic response. More recently Ehlenberger
and Nussenzweig (1977) have examined more precisely the role
of membrane receptors for C3b and C3d on human' phagocytic
cells. It was concluded, from their studies, that:
(a) Both C3b and C3d act as opsonins if the phagocytic
cell has the appropriate receptors.
(b) C3b and IgG have separate but synergistic roles
in phagocytosis.
From these and other findings it is now believed that
the role of C3b and possibly C3d receptors in opsonization is
mainly in establishing contact between the particle and the
phagocytic cell in the adherence phase whereas bound IgG
serves as a trigger for the ingestion phase.
Apart from their participation in phagocytosis other
roles were suggested for the C3b receptor on monocytes and
polymorphonuclear cells. For example, if the C3b coated
particle is non-phagocytosible then exocytosis of lysosomal
content of the polymorphonuclear cell can occur. Also the
interaction between the C3b molecule and the C3b receptor on
the neutrophil may cause certain intracellular changes which
will promote the cytolytic potential of the cell. With
macrophages, the attachment of C3b to the C3b receptor
increases their content of lysosomal enzymes within the
endoplasmic reticulum and hence enhance their bactericidal
properties. The same signal can promote the production
of C3a by macrophages which can act as a specific cytolytic
agent for certain tumour cells (Schorlemmer and Allison,
1976).
(ii) C3b receptors on lymphocytes
The role of C3b receptors on lymphocytes has been
extensively studied but the results are conflicting. The
finding that the interaction between C3b and C3b receptors
on lymphocytes has a mitogenic effect (Hartman and Bokisch,
1975) was not confirmed by other workers (Waldmann and
Lachmann, 1975; Koopman et al, 1976). A patient with the
genetic KAF deficiency, who had continuously high levels of
circulating C3b, did not show any lymphocyte changes (Alper
et al, 1970).
It was suggested that the C3b receptor on lymphocytes
may facilitate the antibody response to antigens. This
can be achieved either by promoting bridge formation between
the antigen carrying macrophages and lymphocytes or by
enhancing the binding of monomeric antigen to the lymphocyte
via the C3b receptor.
The interaction between the C3b receptor on the
lymphocyte and C3b can induce the release of a mononuclear
chemotactic factor leading to the recruitment of the mono¬
nuclear cells to the sites of allergic reaction (Koopman
et al, 1976; Sandberg et al, 1975).
More important, but perhaps more difficult to ascertain,
is the role of complement in the induction of the immune
response through the C3b receptor on lymphocytes (reviewed
by Pepys, 1976). It was shown that the IgG, IgA and IgE
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antibody responses to thymus dependent antigens were
suppressed in mice which were depleted of C3 by a purified
factor from cobra venom (CVF). The IgM response to thymus
independent antigen was unaffected. Various workers have
attempted to simulate these situations by using in vitro
models (Waldman and Lachmann, 1975; Feldmann and Pepys,
1974), but the results were equivocal. More convincing
evidence for the role of the C3b receptor on lymphocytes
in the induction of the immune response was provided by the
work of Klaus and Humphrey (1977). They showed that since
CVF is a potent thymus dependent antigen in mice, the C3
depletion produced following CVF injection is transient and
subsequent injections of CVF are neutralised by antibody.
However, prolonged C3 depletion can be produced by repeated
injection of CVF in mice which fail to produce antibody
response. These mice were unable to localise antigens on
the surface of the dendritic reticular cells within the
lymphoid tissue and, therefore, the formation of germinal
centres and the development of B cell memory was not achieved.
This suggests that one role of complement in the induction of
the immune response is to facilitate the localisation of
antigens on the surface of the dendritic cells through
their C3b receptors.
(iii) C3b receptors on yK-cells?
The role of complement receptors in K-cell activity
has been studied by several workers (Van Boxel et al, 1974;
Perlmann et. al, 1969; Perlmann et al, 1974). Perlmann
et al (1975) have shown that cell-bound C3b did not trigger
cytolysis, but it can potentiate the antibody-dependent
damage of target cells. Preliminary results (Grant, A.,
unpublished observations) have also indicated that the
presence of bound C3b on sensitized sheep red cells can
significantly potentiate the cytolytic ability of human
lymphocytes. It seems likely, therefore, that the enhancing
role of bound C3b on K-cell cytolysis is due to the amplifica¬
tion of the attachment phase which is an essential preliminary
step in such reactions.
(iv) C3b receptors on human glomeruli
Gelfand et al^ (1975) described the presence of a
receptor for bound C3b on normal human glomerular tissues.
Later the receptor site was located, using scanning electron
microscopic studies, on the visceral epithelial cells of the
renal glomerulus (Shin et al, 1977). The presence of this
receptor may explain the pathogenesis of immune complex
deposition in the glomeruli since one of the known features
of immune complex glomerulonephritis is the deposition of
complement-containing immune complexes in the glomerulus
leading to complement-mediated immune damage.
(v) C3b receptor on primate red cells
There is no known erythrocyte function which can be
regarded as a direct result of interaction between C3b and
C3b receptors on erythrocytes. However, it has been
suggested that the presence of such a receptor may be one
way by which the ingestion of bacteria coated with antibody
and complement can be facilitated since it is thought that
their adherence to the C3b receptor on the erythrocyte will
hold them against a rigid object and hence they can be more
easily ingested (Nelson, 1956). /
(vi) C3b receptors on platelets
C3b receptors are found on the platelets of certain
species. In contrast, human platelets apparently lack
this receptor, although they do bear a receptor for the Fc
portion of IgG and it is thought that this receptor may
substitute for the lack of C3b receptors on human platelets
in certain In vivo reactions. A possible role for C3b
receptors on platelets has been suggested by Henson (1970)
who demonstrated that in the rabbit the release of vaso¬
active amines from platelets is enhanced following their
adherence to C3b coated particles.
2.4 C3d receptors
The presence of this receptor was first detected by
Okaka and Nishioka (1973) on lymphoblastoid cell lines.
They were then shown to be present on a variety of cells
including normal human B lymphocytes (Ross et al, 1973;
Eden et al, 1973) and monocytes. Initially, C3d receptors
were thought to be absent in neutrophils (Ross et al, 1973;
Eden et al, 1973) but recently their presence on human
neutrophils has been reported and it is thought that their
appearance in these cells may be an indication of an earlier
stage of cell maturation (Ross et al, 1978).
The function of the C3d receptor is thought to be
similar to that of the C3b receptor on phagocytic cells,
i.e. they enhance the attachment phase of phagocytosis.
C. RECEPTORS FOR IMMUNOGLOBULINS AND COMPLEMENT ON THE
EOSINOPHIL LEUCOCYTE
The first evidence that the eosinophil leucocyte may
have membrane surface receptors for complement and IgG was
provided by Henson (1969) who observed that guinea pig
eosinophils contaminating his neutrophil preparations formed
rosettes with erythrocytes coated with IgG and also with
IgM and complement. The report of Butterworth et al (1975),
where human eosinophils obtained from normal healthy
individuals were shown to be the main effector cells
mediating antibody-dependent cell mediated damage of
schistosomula of Schistosoma mansoni, has further stimulated
a number of laboratories to study animal and human eosinophils
for the presence of receptors for immunoglobulin and
complement. Rabellino and Metcalf (1975) examined cells
from mouse eosinophil colonies, grown in vitro, for the
presence of IgG and complement receptors and compared them
with cells from macrophage and neutrophil colonies. They
found that in contrast to macrophage and neutrophil
preparations, eosinophils showed no detectable C3 receptors.
However, after 7 days in culture 50-60% of eosinophils
showed receptors for rabbit IgG. Later, Butterworth et al
(1976) reported that guinea pig peritoneal eosinophils were
capable of reacting in a rosette assay with IgG from guinea
pig and pig, but not from rabbit.
While studying human eosinophils to compare the
structural and functional properties of cells from normal
individuals and eosinophilic patients, Tai and Spry (1976)
and Spry and Tai (1976) found that eosinophils obtained from
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patients with eosinophilia associated with various clinical
conditions have receptors for rabbit IgG. However, they
were unable to detect the presence of this receptor for
rabbit IgG on eosinophils from normal individuals. They
also showed that eosinophils from patients with eosinophilia
and from healthy individuals can form rosettes with EAC3
to a similar extent. These workers suggested that the
presence of a receptor for rabbit IgG on human eosinophils
may be an indication of eosinophil stimulation and
maturation.
Sher and Glover (1976) reported the presence of
receptors for C3 and also for unsensitized sheep red cells
on human eosinophils obtained from patients with eosinophilia
due to various aetiology.
From their extensive study of human eosinophil surface
markers, Gupta et aT (1976) concluded that these cells bear
receptors for aggregated human IgG and for the complement
components C4, C3b and C3d. However, they were unable to
detect receptors for either rabbit IgG or for unsensitized
sheep red cells. Also, they could not detect the presence
of surface immunoglobulins.
More recently Parrilio and Fauci (1978) were unable to
detect EA rosettes with human eosinophils obtained from
normal individuals, although they were present on cells
obtained from eosinophilic patients tested. They were also
able to demonstrate the presence of complement receptors on
eosinophils from both normal individuals and from patients
with eosinophilia.
For some time various workers have attempted to detect
36
the presence of IgE on the surface membrane on the eosinophil
leucocyte. However, Ishizaka et al (1970) were unable to
demonstrate the uptake of I-radiolabelled IgE aggregates
on the eosinophil whereas they were able to demonstrate
such an uptake on to basophils. Similarly, Sullivan et al
(1971) who utilised electron microscopy with ferritin-labelled
anti-IgE could detect the presence of IgE on basophils but not
on eosinophils. However, Hubscher (1975a) reported that some
patients with ragweed antigen hypersensitivity have IgE
demonstrable on 20-30% of their eosinophils and that these
cells are capable of binding ragweed antigen. Also
Fujita et al (1975) have shown that eosinophils recovered
from the nasal secretions of patients with ragweed allergy
have bound and possibly phagocytosed IgE-ragweed antigen
complexes.
In summary, it seems that membrane receptors for both
complement and immunoglobulin may be present on both human
and animal eosinophils, although some controversy still
remains. It is possible that differences in techniques
used might explain some, if not all, of these discrepancies.
/
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THE AIMS OF THE PRESENT STUDY
The eosinophil leucocyte was first characterized by
Paul Ehrlich in 1879. Since that time this cell has been
a source of interest to numerous investigators, but despite
thousands of publications the primary function of the
eosinophil remained an enigma although very recently several
functional roles have been suggested for the cell in relation
to helminth diseases and in immediate-type hypersensitivity
(reviewed by Kay, 1976).
An increase in the number of eosinophils both in
tissues and the peripheral blood is associated with many
clinical conditions. They include allergic diseases such
as extrinsic bronchial asthma, atopic dermatitis and
allergic rhinitis; hypersensitivity to numerous drugs;
pulmonary eosinophilia; certain malignant conditions
including Hodgkin's disease; a number of connective tissue
disorders and the hypereosinophilic syndrome. In terms of
world population the commonest associations with eosinophilia
are almost certainly helminth diseases.
The functions of the eosinophil in immediate-type
hypersensitivity reactions are probably diverse and,
therefore, point to the versatility of the cell in various
inflammatory states. It may have a regulatory role at all
stages of the allergic reaction, namely mediator release,
mediator inactivation and mediator replenishment. Tissues
containing mast cells can be sensitized by IgE (or other
tissue sensitizing antibody) for the antigen-induced release
of chemical mediators of anaphylaxis. These pharmacological
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agents include histamine, slow reacting substance of
anaphylaxis (SRS-A) and an eosinophil leucocyte chemotactic
factor of anaphylaxis (ECF-A). ECF-A selectively attracts
eosinophils from a mixed leucocyte population in vitro (Kay
et al, 1971). Histamine may also contribute to the
infiltration and localization of eosinophils (Clark et al,
1975). Following mediator release an eosinophil-derived
inhibitor of histamine release (EDI) - probably a
prostaglandin - may then inhibit further histamine release
(Hubscher, 1975a, b). Eosinophil histaminase (Zeiger and
Colten, 1974) and arylsulphatase (Wasserman et al, 1975)
are then available for histamine and SRS-A inactivation.
Following mediator release and inactivation a repair process
is initiated which leads to mediator replenishment. The
eosinophil may have an important 'negative* or 'dampening'
role in the repair process also. Depletion of eosinophils
by anti-eosinophil serum (AES) resulted in more rapid
histamine accumulation following cutaneous anaphylaxis (Jones
and Kay, 1976). Therefore, eosinophils may have a regulatory
role in repair following anaphylaxis and so provide a homeo-
static mechanism whereby the antigen-induced release of
pharmacological mediators of anaphylaxis from the mast cells
is not perpetual in situations of continuous antigenic
stimulation.
The clear association between eosinophils and parasites
has encouraged many investigators to examine both the
mechanisms of parasite-induced eosinophilia and the possi¬
bility that the eosinophil is an effector cell in parasite
destruction; a role previously suggested by Kay (1974).
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More recently there have been a number of studies to support
this concept. In 1975 Butterworth et al reported that the
human eosinophil may act as a principal effector cell in an
antibody-dependent damage to schistosomula of Schistosoma
mansoni in vitro. Furthermore, eosinophils from infected
mice were shown to destroy the schistosome eggs in a system
where the cell became 'armedr by a cytophilic antibody
directed against the appropriate egg antigen (James and
Colley, 1976). More recently eosinophils were shown to be
the effector cells in the killing of the epimastigotes from
Trypanosoma cruzi (Sanderson et al, 1977). Using a technique
which depends on the release of RNA from T. cruzi. eosinophils,
in the presence of specific antibody, mediated killing whereas
lymphoid cells had insignificant activity.
From the previously mentioned work it is evident that
the eosinophil leucocyte may be involved, as an effective
cell, in a number of important immunological reactions, all
of which may require effective recognition mechanisms through
which contact between the eosinophils and target cells is
made possible. In the present study the need to define
more precisely the membrane surface receptors for immunoglobulin
and complement was largely stimulated by the report of
Butterworth et al (1975) in which human eosinophils from
normal donors were shown to be the principal effector cells
in antibody-dependent killing of schistosomula in vitro.
In this system the antibody was identified as IgG (Butterworth
et al, 1977b) and the adherence of the eosinophil to IgG-
sensitized schistosomula may be dependent on the presence of
freely available IgG receptors. Although there was no
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apparent requirement for complement in this system, the
possibility that complement may enhance the cytotoxic
capacity of the eosinophil was not excluded. Therefore,
the main objectives set prior to the commencement of the
present studies were:
1. To establish more precisely the presence and
properties of membrane receptors for IgG and complement on
the human eosinophil leucocyte, especially in view of the
conflicting literature reports on the surface markers on
eosinophils (see Introduction).
2. To compare these receptors with those present on the
human neutrophil leucocyte.
3. To study the pharmacological control of the expression
of these receptors by mast cell— derived agents known to be
specifically chemotactic for eosinophils.
4. To establish an in vitro system for the assessment of
the role of the eosinophil as a killer cell against
schistosomula of Schistosoma mansoni.
5. To examine the possible relationship between IgG and
complement receptors on eosinophils and schistosomula killing
by studying the killing mechanism in the presence of antibody
and/or complement.
6. To compare the schistosomula killing capacity of human
eosinophils and other human leucocytes.
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CHAPTER III - MATERIALS AND METHODS
/
43
CHAPTER III - CONTENTS
1.0 BUFFERS p. 44
2.0 CHEMICALS AND REAGENTS p. 45
3.0 SHEEP RED BLOOD CELLS (E) p. 47
4.0 RABBIT, BABOON AND HUMAN ANTISERA p. 48
5.0 SENSITIZATION OF SHEEP RED BLOOD CELLS p. 51
6.0 PREPARATION OF COMPLEMENT COATED SHEEP
RED CELLS p. 52
7.0 PREPARATION OF HUMAN EOSINOPHILS, NEUTROPHILS
AND MONONUCLEAR CELLS p. 55
8.0 PREPARATION OF HUMAN RED CELLS p. 58
9.0 ERYTHROCYTE-ANTIBODY (EA) AND ERYTHROCYTE-
ANTIBODY-COMPLEMENT (EA0 ROSETTE FORMATION .. p. 59
10.0 IMMUNOFLUORESCENCE STUDIES p. 61
11.0 TREATMENT OF LEUCOCYTES WITH
PHARMACOLOGICAL AGENTS p. 63
12.0 PREPARATION OF HUMAN LUNG ANAPHYLACTIC
DIFFUSATE p. 64
13.0 PREPARATION OF SCHISTOSOMULA p. 65
14.0 SCHISTOSOMULA KILLING ASSAY p. 67
44
1.0 BUFFERS
1.1 Dextrose-gelatin-Veronal buffer (DGVB++)
This was prepared on the day of the experiment by
mixing equal volumes of isotonic Veronal buffered saline
(containing 0.0015 M Ca++, 0.0005 M Mg++ and 0.1% gelatin
Veronal buffer (GVB++)) with 5% dextrose in water containing
the same concentration of Ca++ and Mg++ (D5W++), as described
by Nelson et al (1966).
1.2 Gelatin-Veronal buffer (GVB )
This was prepared as for GVB but without the addition
of Mg++ and Ca++.
1.3 0.01 M EDTA GVB" and 0.04 M EDTA GV3~"
A stock solution of 0.086 M EDTA, pH 7.4, was prepared
and kept at 4°C. To prepare 0.04 M EDTA GVB and 0.01 M
EDTA GVB the stock solution was diluted in GVB .
1.4 Tyrode*s buffer
This was prepared by mixing 40 ml of Tyrode*s A (see
below) with 1 g of NaHCOg, 1 g D-glucose, 1 ml 20% CaClg
and 0.4 ml 25% MgClg and adjusting the volume to 1 litre
with distilled water. The pH was then adjusted to 7.4.
Tyrode*s A
A stock solution containing 200 g NaCl, 5 g KC1 and
1.625 g Na2H2PO^ in 1 litre of distilled water was prepared
and stored at 4°C.
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2.0 CHEMICALS AND REAGENTS
Reagents were obtained as follows.
2.1 Eosinophil chemotactic factor of anaphylaxis (ECF-A)
tetrapeptides
The valyl- (HC1) (Val-Gly-Ser-Glu), molecular weight
427, and alanyl-peptide (HC1) (Ala-Gly-Ser-Glu), molecular
weight 497, were a gift from Dr. R. Camble (I.C.Io Limited,
Pharmaceuticals Division, Alderley Park, Macclesfield).
2.2 Histamine acid phosphate was purchased from BDH
Chemicals, Poole.
2.3 Bradykinin triacetate and 5-hydroxytryptamine were
purchased from Sigma, Kingston-upon-Thames.
2.4 Prostaglandins E^, E2 and F2q. were supplied by Dr. John
Pike, Upjohn Company, Kalamazoo, U.S.A.,
2.5 Imidazoleacetic acid hydrochloride (ImAA) chromato-
graphically free of histidine, histamine acid isopropylester,
98.8% pure, l-methyl-4-imidazoleacetic acid hydrochloride
(1,4-MeImAA), L-histidine, free base, 1,4-methylhistamine
dihydrochloride (1,4-MeHm), N-acetylhistamine (N-AcHm), all
chromatographically homogenous, were obtained from Calbiochem
Limited, San Diego, California, U.S.A.
2.6 Timothy grass pollen was a generous gift from Beecham
Research Laboratories, Betchworth, Surrey.
2.7 Monospecific anti-C3d was purchased from the Netherlands
Red Cross Blood Transfusion Service, Amsterdam.
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2.8 Anti-human C3 was a generous gift from Professor
D.K. Peters, Department of Medicine, Royal Postgraduate
Medical School, London.
2.9 Anti-human C4 was kindly supplied by Dr. E.A. Dewar,
Department of Pathology, University of Edinburgh.
2.10 Bovine serum albumin was purchased from Miles
Laboratories, Slough, and aggregated according to the method
of Dickler (1974).
2.11 Fluorescent anti-human C3 and anti-human C4 were
purchased from Hoechst (Behring), Middlesex.
2.12 Human C2-deficient serum was kindly supplied by
Dr. J.F. Mowbray, St. Maryvs Hospital Medical School,
London.
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3.0 SHEEP RED BLOOD CELLS (E)
3.1 Sheep blood was drawn aseptically into sterile
Alsever's solution and kept at 4°C. Immediately before
use the red cells were washed twice in cold saline solution
(0.15 M NaCl), once in 0.01 M EDTA GVB and then adjusted
to the required concentration, in the same buffer,
spectrophotometrically.
3.2 Treatment of sheep red blood cells with aminoethyl-
isothiouronium bromide hydrobromide (AET)
This was performed according to the method of Kaplan
and Clark (1974). Briefly, AET (Aldrich Laboratories,
Milwaukee, Wisconsin, U.S.A.) was prepared freshly as a
0.143 M solution and the pH was adjusted to 9.0. To 1 ml
of washed and packed sheep red cells, 4 ml of AET solution
were added. The suspension was thoroughly mixed and
incubated at 37°C for 15 min with frequent agitation.
The cells were centrifuged and the ceil pellet was washed
four times with cold saline before they were finally
adjusted to yield a 10% solution using medium 199/20% FCS.
In all the experiments mentioned in this study the AET-
treated sheep red cells were used immediately after
treatment.
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4.0 RABBIT. BABOON AND HUMAN ANTISERA
4.1 Rabbit anti-sheep red blood cells (A)
Multiple injections of sheep red blood cell stroma
were administered to rabbits as described by Rapp and Borsos
(1970). The IgG and IgM fractions of the antiserum were
obtained by gel filtration on Sephadex G-200. Briefly, a
2.6 x 80 cm column was used with 0.05 M tris in 0.15 M NaCl,
pH 7.4, as the eluting buffer. Four millilitres of the anti-
sheep red cell serum was applied to the column and 2 ml
fractions were collected. The active fractions in the
first two protein peaks were located, pooled and divided
into 1 ml portions and kept at -20°C. The presence of IgG
and IgM in each pool was confirmed by immunoelectrophoresis.
Finally the optimal haemolysin titre was determined for each
pool (Rapp and Borsos, 1970).
4.2 Human immunoglobulin G (IgG)
This was kindly prepared by Dr. S. Moore, Edinburgh
Blood Transfusion Service, by diethylaminoethyl (DEAE)
cellulose ion exchange chromatography. Its purity was
verified by radial immunodiffusion using ultra-low level
plates (Hyland).
It was divided into two portions, one of which was
used to prepare heat-aggregated material and the other was
used as the normal unaggregated control. The heat-
aggregated material was prepared according to the method
of Dickler and Kunkel (1972) by heating 2.5 ml of the IgG
suspension at 63°C for 30 min. The resultant aggregates
were homogenized in phosphate buffered saline (PBS) and
finally diluted to give a protein concentration of
1.2 mg/ml.
4.3 Human anti-schistosomula sera
(a) Three batches of human anti-schistosomula serum were
used. They were kindly supplied by Dr. D.S. Ridley,
Hospital for Tropical Diseases, London, Dr. W.N. Beesley,
Liverpool School of Tropical Medicine and Dr. M.O. Gad el
Rab, Department of Microbiology, University of Khartoum.
All the sera were inactivated for 1 hr at 56°C before
being tested separately for their schistosomula-cytotoxic
activity. Each batch was then pooled, aliquoted into
1 ml portions and kept at -20°C until use.
(b) Preparation of the IgG fraction from human anti-
schistosomula serum
Serum was fractionated by DEAE-cellulose ion exchange
chromatography (DE-52) using 0.01 M Tris, 0.002 M EDTA in
0.025 M NaCl (pH 7.5) as the eluent buffer. Three milli-
litres of serum were applied to 30 ml of DEAE-52 in a small
column and 1 ml fractions were collected. The fractions
containing the protein peak were pooled and dialysed against
distilled water overnight. The IgG was freeze-dried and
reconstituted in medium 199 to the original serum volume.
The purity was tested by immunodiffusion against low level
plates (Hyland). It was found to be free from IgA and IgM.
Finally it was aliquoted and kept at -20°C until required.
4.4 Human anti-D sera
The main batch of anti-D serum used in the experiments
described here was kindly supplied by Dr. S.J. Urbaniak,
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Edinburgh Blood Transfusion Service. It was prepared as
follows. Several plasmapheresis packs were obtained from
a donor who aborted due to haemolytic disease of the newborn
as a result of anti-D immunisation. The plasma was converted
to serum by the addition of one drop of thrombin (Parke-Davis)
per ml of plasma. After incubation at 37°C for 1 hr, the
material was centrifuged and the clear supernatant transferred
into clean containers. The serum was then heat inactivated
at 56°C for 30 min. The specificity of the anti-D was
confirmed by testing against a panel of standardised red
cells by conventional saline, enzyme and indirect antiglobulin
methods.
Other batches of anti-D sera which were used in some
experiments were supplied by Mr. C. Darg, Edinburgh Blood
Transfusion Service. They were prepared as described above.
All anti-D batches were aliquoted and kept at -40°C until
use.
4.5 Baboon anti-schistosomuia serum
This was a generous gift from Dr. Anthony E.
Butterworth, Robert B. Brigham Hospital, Boston, U.S.A.
It was also heat inactivated for 1 hr at 56°C, divided
into 1 ml portions and kept at -20°C until use.
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5.° SENSITIZATION OF SHEEP RED BLOOD CELLS
Either IgG or IgM fractions of the rabbit anti-sheep
red cells were used.
5.1 Sensitization with IgM anti-sheep red cells
About 5 ml of sheep red cells in Alsever?s solution
were washed (2,000 rpm for 10 min at 4°C) twice in 0.15 M
NaCl, once in 0.01 M EDTA GVB and the cell concentration
was adjusted to 1 x 10® cells/ml in 0.01 M EDTA GVB .
To these calibrated red cells the IgM fraction was added
in amounts causing optimal sensitization needed for
complement fixation, as calculated by determining the optimal
haemolysin titre. In experiments where the presence of
receptors for IgM was tested the sensitization was achieved
by using the maximum subagglutinating IgM titre. The
mixture was incubated at 37°C for 30 min in a shaking water
bath, and at 0°C for 30 min with frequent mixing. The cells
were then washed once in 0.01 M EBTA GVB and twice in
DGV3++. These cells are kept in DGVB++ at 4°C (EA^ab).
5.2 Sensitization with IgG fraction
The procedure was the same as described for IgM except
that the titre of IgG was always the maximum subagglutinating
titre. After the final wash the sensitized cells were kept
in DGVB++ at 4°C (EA^ab).
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6.0 PREPARATION OF COMPLEMENT COATED SHEEP RED CELLS
6.1 Human purified complement components
Human CI was prepared by euglobulin precipitation
according to the method of Vroon et al (1970).
Human C4 was prepared by sequential precipitation and
ion exchange chromatography on DEAE-Sephadex and carboxy-
methyl (CM)-Sephadex. The eluents used for the DEAE-
column were (a) 0.05 M Tris (hydroxymethylaminomethene),
0.002 M EDTA, pH 8.0, and (b) 0.05 M Tris, 0.5 M NaCl,
0.002 M EDTA, pH 8.0, and for the CM-Sephadex column were
(a) 0.05 M acetate, 0.002 M EDTA, 0.05 M NaCl, pH 5.0 and
(b) 0.05 M acetate, 0.002 M EDTA, 0.3 M NaCl, pH 5.0. C4
activity in the different fractions was detected antigenically
and haemolytically; fractions showing maximum activity were
pooled, concentrated, aliquoted and kept in liquid nitrogen
until use. The C4 haemolytic titre was determined according
to the method of Rapp and Borsos (1970).
Human C2 was kindly supplied by Dr. K. Whaley,
Department of Pathology, Western Infirmary, Glasgow. Two
batches of purified human C3 were used, the first was a
generous gift from Professor D.K. Peters, Department of
Medicine, Royal Postgraduate Medical School, London. The
second batch together with human C5, C6, C7, C8 and C9 were
purchased from Cordis Laboratories (Miami, Florida, U.S„A.).
Purified human C3b inactivator was kindly supplied by Professor
P.J. Lachmann, Laboratory of Molecular Biology, University of
Cambridge, but in some experiments Cordis C3b inactivator was
used. All these complement components were functionally pure
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and free of other haemolytically active components as assayed
by effective molecular titration as described by Rapp and
Borsos (1970).
6.2 For the preparation of complement coated intermediates,
sheep red cells sensitized with rabbit IgM (EA^ ) as
described in 4.1 were used.
y»o V*
(a) EA^ were mixed with 400 effective molecules of human
CI per red cell. The mixture was incubated for 90 min at
0°C with periodic shaking. It was then washed once in
DGVB++ and kept as EA^abClhu (EAC1).
(b) EA^abClbu4hu cells were prepared by the addition of
4000 effective molecules of human C4 per EAC1 cell. The
mixture was incubated at 37°C for 30 min. The cells were
then washed four times in DGVB++ and kept as EAj^abClbu4bu
(EAC14) cells. The presence of bound C4 on sheep red cells
was detected by agglutination with anti-human C4, by showing
a positive fluorescence with fluorescent anti-human C4 or by
detection of red cell lysis following the completion of the
complement cascade, i.e. by addition of C2-C9. In the
experiments designed to detect C3 rosettes the amount of C4
added per EAC1 was only 400 effective molecules (not
sufficient to form C4 rosettes with either eosinophils or
neutrophils).
(c) EA^abClbu4bu2bu cells were prepared by the addition
of 50 effective molecules of human C2 per EAC14 cell and the
mixture was incubated for 10 min at 30°C. The cells were
then centrifuged at 2000 rpm at 4°C for 10 min. The
supernatant was discarded and the pelleted cells were kept
at 0°C as EA^abClhu4hu2hu (EAC142).
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(d) EA^abCl^lu4llu2hu3hu were prepared as follows: 400
effective molecules of human C4 were added to EAC1 and the
mixture was incubated for 30 min at 37°C and washed four
times in DGVB++. To this EAC14 intermediate (which had
insufficient bound C4 to form rosettes with either neutrophils
or eosinophils), 50 effective molecules of human C2 were added
and the mixture was incubated at 30°C for 10 min without
washing. To these EAC142 cells, 2500 effective molecules
of human C3 were added. The mixture was incubated at 37°C
for 30 min and the cells were washed twice in DGVB and
used as EA^a^>Cl^u4^lu2^lu3^lu (EAC3b) cells. The presence of
bound C3 on the cells was confirmed by agglutination with
anti-human C3, by their positive reaction with fluorescent
anti-human C3 and by the addition of C5-C9 to detect lysis.
(e) EAC1423d intermediates were prepared by treating 0.5 ml
g
of EAC3b cells containing 1 x 10 cells/ml with 0.5 ml of the
C3b inactivator. The mixture was incubated for 1 hr at
37°C. The cells were then washed twice in DGVB++ (EAC3d).
The presence of the C3d cells was confirmed by testing the
C3d cells for immune adherence with human group O Rh positive
erythrocytes. In all these experiments 90-95% inhibition of
immune adherence was aimed at. On some occasions the
addition of C3b inactivator was repeated and a longer
incubation time was found to be necessary for complete
conversion of the C3b cells to C3d cells. The EAC3d cells,
in contrast to the EAC3b cells, were not lysed in the presence
of C5-C9. However, they were agglutinated with monospecific
anti-C3d, as were the EAC3b cells.
/
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7.0 PREPARATION OF HUMAN EOSINOPHILS, NEUTROPHILS AND
MONONUCLEAR CELLS
7.1 Eosinophils and neutrophils
Blood either from patients with eosinophilia or from
healthy controls was drawn into plastic Universals containing
10 units of preservative free heparin (Evans Medical,
Liverpool) per ml. The red cells were sedimented with
70% dextran (Lomodex 70, Fisons Pharmaceuticals,
Loughborough); one part dextran to four parts blood v/v,
for 60 min at room temperature. The leucocyte-rich plasma
was then layered on to sodium metrizoate (Nyegaard & Co.,
As, Oslo, Norway), specific gravity 1.148 at 4°C, in 15 ml
plastic conical centrifuge tubes and centrifuged at 4°C for
40 min at 400 x G (Day, 1970).
The pellet containing red blood cells and granulocytes
was resuspended in ammonium chloride solution to lyse the
erythrocytes (see below). The granulocytes were then washed
twice in medium 199 (Flow Laboratories, Irvine, Ayrshire),
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pH 7.4, and the cell count was finally adjusted to 2 x 10 /ml
(for rosette experiments) in the same medium. These cell
suspensions contained both eosinophils and neutrophils but
were virtually free of mononuclear cells.
For the studies described in Fig. 29 in which suspensions
of highly purified granulocytes of varying eosinophil/
neutrophil ratios were required, the technique of Wong and
Wilson (1975) was used either alone or in combination with
the method mentioned earlier. Wong and Wilson*s method was
modified slightly and was briefly as follows: two Ficoll-
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Conray solutions A and B were prepared. Solution A
contained 11.2 g of Ficoll (Pharmacia, Uppsala, Sweden)
and 20 ml of Conray 280 (May & Baker, Dagenham) in 100 ml
of distilled water; solution B contained 7.2 g of Ficoll
and 20 ml of Conray 280 in 100 ml distilled water. These
stock solutions were kept at 4°C and used for up to 7 days.
On the day of the experiment 200 ml of blood were withdrawn
from a normal volunteer and taken into plastic Universals
containing 10 units/ml of preservative-free heparin. Ten
millilitre portions of blood were layered on to 10 ml of
solution B in plastic Universal containers and the red cells
were allowed to sediment for 1 hr at room temperature. The
leucocyte-rich plasma was removed and further layered, in
15 ml plastic centrifuge tubes, on to a gradient consisting
of 3 ml of solution B which in turn had been gently placed
on 3 ml of solution A so that an interface was formed between
them. The tubes were then centrifugea at 1500 x G for
15 min at 4°C. Mononuclear cells sedimented between the
plasma and solution B, and neutrophils at the interface
between solution A and solution B, whilst the red cells and
the eosinophils were pelleted at the bottom. The eosinophil
and neutrophil layers were collected and the contaminating
red cells were lysed using ammonium chloride (see below).
Each cell suspension was washed twice in medium 199 and a
differential white cell count was performed. To obtain
granulocyte preparations of varying eosinophil enrichment,
equal volumes of cell suspensions from different tubes,
prepared either by this method or in combination with that
0
of Day, were adjusted to 4 x 10 total granulocytes per ml
and mixed to obtain the required eosinophil/neutrophil
ratio.
7.2 Preparation of mononuclear cells
These were prepared essentially by a modification
of the method of Bflyum (1968). Blood was collected in
heparinized containers, diluted in 0.15 M NaCl (1:4) and
then layered gently over Ficoll-Hypaque solution (specific
gravity 1.077) in 15 ml conical plastic centrifuge tubes.
The tubes were centrifuged for 25 min at 400 x G at 4°C.
The mononuclear layer which sedimented at the interface
was collected, washed twice in medium 199 and the cell count
g
was adjusted to 2 x 10 /ml (for rosette experiments) or
0
4 x 10 cells/ml (for enhancement and schistosomula
experiments).
7.3 Lysis of contaminating red blood cells
Contaminating red cells were lysed by treatment with




and its pH was adjusted to 7.4. Cell pellets were re-
suspended in about 5 ml of ice cold lysis solution for
5 min at 0°C with frequent mixing. The mixture was then
centrifuged for 10 min at 4°C. The leucocytes, which are
now free of contaminating red cells, were washed twice in
medium 199 and adjusted to the required concentration.
The viability of these cells was always greater than 95%.
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8.0 PREPARATION OF HUMAN RED CELLS
Venous blood samples were obtained from normal donors
or laboratory personnel of known ABO and rhesus groups.
The rhesus types were confirmed by routine blood banking
methods. The following two types were used throughout
in experiments involving the use of human red cells:
Group O rhesus positive OR]^ (CDe/CDe)
ORgRg (cDE/cDE)
8.1 Papainization of human red cells
Five drops of red cell suspension were mixed with
an equal volume of 1% papain in sterile saline (BDH papain,
papaya) for 4 min at room temperature. The cells were




9.0 EA AND EAC ROSETTE FORMATION
One-tenth millilitre of E, EA or EAC containing
8 ++
1 x 10 cells/ml in DGVB was added to an equal volume
of granulocyte or mononuclear cell suspension in medium
g
199 containing 2 x 10 cells/ml. The mixture was centri-
fuged at 100 x G for 10 min at 4°C. These mixtures, with
the undisturbed pellets, were then incubated at 4°C (for the
E rosettes), 0°C (for EA rosettes) or 37°C (for EAC rosettes)
for the optimum incubation time (see below).
9.1 Rosette inhibition by human heat-aggregated IgG
The granulocytes used in these experiments were
6
adjusted to a concentration of 4 x 10 /ml in medium 199.
Equal volumes (0.5 ml) of granulocyte suspension and
aggregated IgG preparation (containing 1.2 mg protein/ml)
were mixed. The mixture was incubated for 30 min at 4°C
with frequent shaking. The cells were then washed three
times in medium 199 and their concentration was adjusted
0
to 2 x 10 /ml before they were used in the rosette assay.
9.2 Preparation and counting of rosette slides
The pellets, containing both leucocytes and indicator
red cells, prepared as described above, were gently re-
suspended and smears were prepared in duplicate on clean
glass slides. These were dried quickly in air (using a
fan or a hair-dryer), fixed in 95% methanol and stained
with May Grunwald/Giemsa. The staining procedure was as
follows:
(i) Slides were placed in 50% May-Grunwald solution
for 3 min. /
(ii) They were transferred, without rinsing, to 10%
Giemsa solution for 3 min.
(iii) They were destained in buffered distilled water
(pH 6.8) for 2 min.
During staining the slides were usually examined for
the staining density and might be destained for a longer
period if required. They were then allowed to dry and
either sprayed with liquid coverglass (Trycolac) or covered
by D.P.X. mounting medium and sealed with coverslips.
Only leucocytes with three or more adherent red cells
were termed rosettes. In each slide 200 leucocytes were
counted and the number of rosetting cells was expressed as
a percentage of the total number of cells counted.
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10.0 IMMUNOFLUORESCENCE STUDIES
10.1 Detection of receptors for heat-aggregated human
IgG on human granulocytes
For these experiments the granulocyte suspensions
g
containing 5 x 10 /ml in medium 199 were used. Before use
the cells were washed once in fFA buffer * (Difco Laboratories,
Detroit, Michigan, U.S.A.) and 0.5 ml of the granulocyte
suspension was mixed with an equal volume of heat-aggregated
human IgG, native IgG or as a control, heat-aggregated
bovine serum albumin, all containing 1.2 mg/ml protein.
The mixtures were incubated at 0°C for 30 min. The cells
were then washed three times in FA buffer at 4°C. Fluores¬
cent labelled rabbit anti-human IgG (Miles Laboratories,
Slough) was added to the cell suspensions and the mixtures
were incubated for a further 30 min at 0°C. The cells were
again washed three times in cold FA buffer and then re-
suspended in two drops of FA mounting medium (buffered
glycerol) (Difco Laboratories). One drop of the cell
suspension was mounted on a clean glass slide under a
coverslip and the edges were sealed with nail varnish.
The slides (prepared in duplicate for each sample) were
then viewed under ultraviolet light and the number of
fluorescing cells were counted. Only cells with two or
more peripheral fluorescing sites (i.e. non-granular
fluorescence) were deemed positive. In each slide 200
cells were counted and the granulocytes showing positive
fluorescence were expressed as a percentage of the total
number of the granulocytes counted.
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10.2 Detection of various complement components bound
to the tegument of schistosomula of Schistosoma mansoni
One millilitre of schistosomula suspension
(containing 1000 organisms) was incubated at 37°C for 1 hr
with an equal volume of either fresh normal human serum,
human C2-deficient serum, heat inactivated human serum or
the appropriate control (Table VIII). After washing twice
in phosphate buffered saline (PBS) the schistosomula were
incubated at 4°C with fluorescent anti-human C4 or anti-
human C3 for 30 min. Finally the schistosomula were
washed three times in PBS, mounted on clean glass slides and
examined by ultraviolet light.
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11.0 TREATMENT OF LEUCOCYTES WITH VARIOUS PHARMACO¬
LOGICAL AGENTS
The leucocyte cell concentration was adjusted to
0
4 x 10 cell/ml in medium 199, pH 7.4. Equal volumes of
the leucocyte suspensions and solutions containing various
concentrations of the pharmacological agents under study,
or control medium alone, were mixed and incubated in a
shaking water bath at 37°C for 1 hr. The cells were then
washed twice in medium 199 and the concentrations were
0
adjusted finally to 2 x 10 /ml in the same medium. A
portion (0.1 ml) of EAG or EAC red cells containing
8
1 x 10 red cells/ml was then added to an equal volume of
the leucocyte cell suspension. The mixtures were centrifuged
at 100 x G for 10 min at 4°C and the pellets were incubated
either at 0°C (for EA rosettes) or 37°C (for EAC rosettes)
for 30 min. The pellets were gently resuspended and smears
were prepared on clean glass slides in duplicate. The
slides were dried quickly in air, fixed in methanol and
stained with May Grunwald/Giemsa. Leucocytes with three
or more adherent sheep red cells were counted as rosettes.
In each slide 200 cells were counted and the number of
rosetting cells was expressed as a percentage of the total
number of leucocytes counted.
12.0 HUMAN LUNG ANAPHYLACTIC DIFFUSATE
This was kindly prepared by Mr. J. Stewart,
Department of Pathology, University of Edinburgh, from
human lung obtained at surgery, usually in association with
bronchogenic carcinoma, according to the method described
by Turnbull et al (1976). Briefly, lung fragments were
washed in Tyrode's buffer and each gram wet weight of
sliced lung fragment was incubated with 5.4 ml of a 1 in 8
dilution of serum from an individual sensitive to Timothy
grass pollen. After an incubation period of 18 hr at room
temperature the lung fragments were washed twice in Tyrode*s
buffer and challenged with 9 ml of the same buffer,
containing 0.2 pg/ml of purified Timothy grass pollen
extract (TGP). Following incubation for 15 min at 37°C
the diffusate was removed and stored at -85°C until use.
Appropriate controls in which unsensitized lung was
challenged with the same amount of antigen (TGP) or
sensitized lung was challenged with TyrodeTs buffer alone,
were prepared in parallel. The histamine content in these
diffusates was assayed on atropinized guinea pig ileum
according to the method of Brocklehurst (1960).
13.0 PREPARATION OF SCHISTOSOMULA
13.1 The parasite cycle
A Puerto Rican strain of Schistosoma mansoni was
maintained in laboratory-bred Biomphalaria glabarata and
outbred Parkes mice according to the method of Smithers
and Terry (1965).
13.2 Mechanical transformation of cercariae to schistosomula
Schistosomula were kindly prepared by Dr. S.R. Smithers,
Division of Parasitology, National Institute for Medical
Research, Mill Hill, London, according to the method of
Ramalho-Pinto et al (1974). Briefly, cercariae freshly
shed from snails were concentrated by the addition of
penicillin-streptomycin, followed by chilling and centrifuging
at 1000 rpm for 30 sec. One millilitre of deionized water
was added to the pellet and the suspension thoroughly mixed
using a Vortex mixer (Fisons Scientific, Loughborough) for
1 min. This effected the rupture of tails from bodies,
which were subsequently separated by sedimentation in Hank*s
buffered salt solution. The cercarial bodies were then
incubated for 3 hr in RPMI-1640, 20 mM Hepes. The
schistosomula were transported by train from London to
Edinburgh at ambient temperature, and were used in the
experiments described here approximately 24 hr after their
preparation.
13.3 Preparation of complement coated schistosomula
One thousand schistosomula (Sch) contained in 1 ml
were sensitized by incubation with 1 ml of human anti-
schistosomula serum (A) for 3 hr at 37°C and washed twice
in DGVB++, pH 7.4 (SchA). SchA were then incubated for
15 min with 40,000 effective molecules per schistosomulum
of human CI at 37°C and washed once in DGVB++(SchACl).
For the preparation of SchAC14, 40,000 molecules of
purified human C4 were added to SchACl and the mixture
O 4.4.
was incubated for 30 min at 37 C and washed twice in DGVB .
Five thousand effective molecules of human C2 were then
added per SchAC14 and the mixture was incubated at 30°C for
10 min without washing (SchAC142). Increasing concentrations
5 5 5
of purified human C3 (i.e. 1 x 10 , 2 x 10 , 3 x 10 and
4 x 10 effective molecules per schistosomulum) were added
to SchAC142 and the mixtures were incubated for 30 min at
37°C and washed twice (SchAC1423). Bound C3b was identified
on schistosomula by the use of fluorescent anti-human C3.
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14.0 SCHISTOSOMULA KILLING ASSAY
The experiments were performed in flat-bottomed
microtitre plates (Sterilin, Middlesex). Except in
experiments performed to determine the optimal effector
cell:target ratios, the ratio of leucocytes to schistosomula
was 4000:1. The reaction volume was 0.4 ml for each
experimental system and each treatment was performed in
duplicate and sometimes in quadruplicate. These experi¬
mental systems were (a) 'antibody alone®, 0.1 ml of baboon,
human anti-schistosomula serum or its IgG fraction (in
medium 199), 0.1 ml of schistosomula, 0.1 ml of leucocytes
and 0.1 ml of medium 199; (b) 'complement alone®, 0.1 ml
of fresh autologous (in respect to the leucocyte donor)
serum, 0.1 ml of schistosomula, 0.1 ml of leucocytes and
0.1 ml of medium 199; (c) 'antibody and complement®,
0.1 ml of antibody (as in (a)), 0.1 ml of complement (as
in (b)), 0.1 ml of schistosomula and 0.1 ml of leucocytes.
The controls were schistosomula (0.1 ml) incubated with
(i) medium 199 (0.3 ml), (ii) leucocytes (granulocytes or
mononuclear cells) (0.1 ml) and medium 199 (0.2 ml) or
(iii) leucocytes (0.1 ml), heat inactivated (56°C for 1 hr)
fresh autologous serum (0.1 ml) and medium 199 (Q2 ml).
In addition, schistosomula (0.1 ml) were also incubated
with antibody as in (a), fresh autologous serum (0.1 ml)
and medium 199 (0.1 ml) in the absence of leucocytes.
The microtitre plates were incubated for 18 hr at
37°C in an atmosphere of 5% COg and 95% air. Schistosomulum
death was determined by direct light microscopy. Only
motile schistosomula (Schrn) or schistosomula killed by
68
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adherent leucocytes (Sch ) were counted. Dead schistosomula
were recognised by their absence of movement, although in
some experiments cytotoxicity was confirmed by their





Some non-viable schistosomula (Schnv) were invariably
present in the suspension prior to treatment and their
number usually increased slightly during the experimental
period. However, they were easily recognised by their
relative opacity, flattened appearance and lack of motility.
The Schnv present in those control or test wells containing
leucocytes were not counted. The controls containing
antibody and complement in the absence of leucocytes, were
calculated by subtracting the number of SchnV contained in
medium 199 alone.
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1.0 INTRODUCTION
The presence of membrane surface receptors for specific
immunoglobulins and various complement components has been
identified on a variety of human and animal haemopoietic cells.
These receptors appear to be part of a cell membrane recogni¬
tion system which may be very important. In the case of
the lymphocyte, the receptors may represent the recognition
link between an antigen on the outside of the cell and the
genetic capacity of the lymphocyte to respond to stimulation.
For phagocytic cells the receptors may be required for
membrane attachment and subsequent phagocytosis. In
addition, these surface receptors have permitted more
precise identification of subpopulations of cells, e.g. T
and B lymphocytes.
Most of the studies on surface receptors relate to
cells of the lymphoid series and mononuclear phagocytes,
although the presence of surface receptors for IgG and
complement on human or animal granulocytes was also
described. For example, the presence of receptors for
human IgG (Messner and Jelinek, 1970), C3b (Eden et al, 1973)
and C4 (Ross and Polley, 1974) on human neutrophils has
been described. Similarly, the presence of IgG (Tai and
Spry, 1976) and C3 receptors on human eosinophils has been
reported (Tai and Spry, 1976; Sher and Glover, 1976).
The present studies, undertaken to define more
precisely the presence of immunoglobulin and complement
receptors on human eosinophils, were mainly stimulated by
the report of Butterworth el; al (1975) who showed that
human eosinophils from normal individuals were the main
73
effector cells in antibody-dependent killing of schistosomula
in vitro.
In the first two sections of this Chapter the results
of experiments performed to study the presence of receptors
for immunoglobulins and various human complement components
on human eosinophils and neutrophils are described. The
main experimental procedure used in these studies was the
rosette technique although in some experiments the immuno-
fluorescent technique was used.
/
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2.0 DETECTION OF RECEPTORS FOR IgG ON HUMAN EOSINOPHILS
AND NEUTROPHILS
2.1 Determination of optimal experimental conditions:
Time course and temperature
Early experiments were designed to establish the
optimal experimental conditions required for maximum rosette
formation between human eosinophils and neutrophils and
sheep red blood cells sensitized with rabbit IgG (EA^ ).
Rosette formation by both eosinophils and neutrophils with
EAq was found to be temperature and time dependent (Figs.
1 and 2). With an increase in the incubation time there
was a corresponding increase in rosette formation which was
maximal at 30 min (81% for neutrophils and 28% for eosino¬
phils) after which the percentage of rosettes for both
cell types remained relatively constant. In some experiments
(not shown) even when the incubation time was increased for
up to 90 min, rosette formation by both eosinophils and
neutrophils was not significantly affected.
i*ctb
Rosette formation by these two cell types with EA^
was tested at three different temperature, 0°C, room
o i*ctb
temperature, and at 37 C. It was found that EAQ rosette
formation was maximal for both eosinophils and neutrophils
at 0°C (Figs. 1 and 2). At higher temperatures, i.e. at
room temperature and 37°C, rosette formation was markedly
decreased and most of the neutrophils and eosinophils showed
evidence of having ingested sensitized red blood cells.
At the optimum experimental conditions, i.e. 0°C and
after 30 min incubation, the percentage of rosetting
neutrophils was approximately two and one-half times that
for eosinophils.
E1&, i
The effect of variation of temperature and time of
incubation on rosette formation by human eosinophils with
EA?ab.
























The effect of variation of temperature and time of
incubation on rosette formation by human neutrophils with
<ab-
The points represent the mean (± 1 S.D.) of five
experiments.
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It was decided to use 0°C and 30 min as optimal
experimental conditions to detect eosinophil and neutrophil
Tclto
EAg rosette formation in the subsequent experiments.
2.2 Effect of increasing IgG concentrations on eosinophil
1*3. fo
and neutrophil rosette formation with EA^
In these experiments , sheep red cells were sensitized
with increasing amounts of IgG prior to incubation with
eosinophils and neutrophils. The percentages of rosette
formation by both eosinophils and neutrophils was directly
dependent on the amount of IgG (Fig. 3). Again it was
found that using the maximum subagglutination IgG titre
and at the optimal conditions, the percentage of rosetting
neutrophils was between two and three times greater than
the percentage of eosinophil rosettes.
2.3 Inhibition of EA^. rosette formation by eosinophils
and neutrophils by human heat aggregated IgG
When human neutrophils and eosinophils were pre-
incubated at 0°C with a constant amount of heat aggregated
y»o
IgG (as described in the methods) and then tested for EA^
rosette formation by incubating them at 0°C with sheep red
cells sensitized by increasing concentrations of rabbit IgG,
there was a significant decrease in the percentage of
rosettes detected with both cell types (Fig. 4).
2.4 Detection of receptors for human IgG by immunofluorescence
The presence of membrane surface receptors for human IgG
was tested directly by treating the granulocyte cell suspension









The effect of increasing concentrations of rabbit IgG on
human neutrophil and eosinophil rosette formation with
EA^ab.




The effect of increasing concentrations of rabbit IgG on
human neutrophil and eosinophil rosette formation with EArak
and their inhibition by heat-aggregated human IgG, G
The points represent the mean (± 1 S.D.) of five
experiments. The degree of significance of inhibition with
heat-aggregated human IgG is expressed as p value as calculated




Eosinophil rosette formation with EA^
(May-Grunwald/Giemsa, x 1000 magnification)
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cells showing positive peripheral fluorescence after the
addition of fluorescein-labelled monospecific rabbit anti-
human IgG (Fig. 5). With both cell types the number of
fluorescing cells with heat aggregated IgG was significantly
greater (p <0.001) than with native unaggregated human IgG
or with heat aggregated bovine serum albumin. As with
EAq rosettes, the percentage of fluorescing neutrophils
was about two and one-half times greater than that of the
fluorescing eosinophils.
2.5 Detection of receptors for human IgG using human Rhesus
positive red cells sensitized with anti-D sera
In these experiments human red cells (O R^R-^ or O R2R2^
were sensitized with human anti-D sera and then incubated
with eosinophils, neutrophils and monocytes to detect
rosette formation.
There was no rosette formation between these red cells
sensitized with any of the anti-D sera tested and either
eosinophils or neutrophils. However, in all the experiments
performed the monocytes formed rosettes. The mean per¬
centage of rosettes formed by monocytes was 47.5% ± 6.5 compared
to less than 5% with either the eosinophils or neutrophils
(Fig. 6).
In a second series of experiments human red cells were
treated by the enzyme, papain, before sensitization. The
use of such enzymes is thought to enhance antibody-red cell
interactions, especially with antibody of the Rhesus blood
group. However, again there was no rosette formation
between the papainized red cells and eosinophils or




The percentage of fluorescing eosinophils and neutrophils
after treatment with heat-aggregated IgG, or controls, and
fluorescent anti-human IgG.














Papainized Human Red Cells
sensitized Red Cells
unsensitized Red Cells
Unpapainlzed Human Red Cells
H sensitized Red Cellsunsensitized Red Cells
Eosinophils Neutrophils Monocytes Eosinophils Neutrophils Monocytes
Fig. 6
The effect of papainization of human red cells (group
O Eh +ve) on rosette formation by human eosinophils,
neutrophils and monocytes with sensitized or unsensitized
human red cells.
The bars represent the mean (± 1 S.D.) of four
experiments.
same papainized red cells formed similar numbers of rosettes
to those detectable using unpapainized erythrocytes (52% ± 5.
(Fig. 6).
2.6 Receptors for IgG on eosinophils from healthy donors
and patients with eosinophilia
Eosinophils obtained from healthy blood donors and
eosinophils from patients with eosinophilia of various
aetiology were tested for their capacity to form rosettes
rafc
with EAq . Before donors were considered healthy for
these experiments they had to fulfil the following criteria:
(a) they should be clinically asymptomatic at the time
of the experiment;
(b) there should be no previous history of conditions
associated with blood eosinophilia;
(c) the blood eosinophil count should be less than
400 cells per cu.mm on the day of the experiment.
In these experiments 15 healthy volunteers fulfilling
the above criteria were compared with 15 patients with
eosinophilia associated with various causes, the majority
being in relation to an exogenous antigen.
Eosinophils from both healthy donors and from eosino-
philic patients formed rosettes with EA^ . There was no
significant difference in the percentage of rosetting
eosinophils between the two groups (Fig. 7). When the
neutrophils from the two groups were compared as regards
to their capacity to form EA^ab rosettes, there was also


































The percentage of eosinophil or neutrophil rosettes with
EAC14 or EAC3b as compared between healthy normal
controls (C) and patients with eosinophilia (E). The EAC14
cells were prepared with 4000 effective molecules of C4 and
the EAC3b cells were prepared with 400 effective molecules
of C4 per cell.
The bars represent the mean (± 1 S.D.). The p values
were calculated by the Student t-test.
N.S. = not significant.
The percentage of either blood eosinophilia or the
percentage of eosinophil and neutrophil EAG rosettes in
15 patients was unrelated to the disease states. In
addition, there was no association between the percentage
X*3.t)
of eosinophilia and the percentage of EAQ neutrophil or
eosinophil rosettes (Table IV).
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3.0 DETECTION OF RECEPTORS FOR IgM AND SHEEP RED BLOOD
CELLS ON HUMAN EOSINOPHILS AND NEUTROPHILS
v» o V\
3.1 Eosinophil and neutrophil EA rosettes
Sheep red cells sensitized with rabbit IgM were tested
for their capacity to form rosettes with human eosinophils
and neutrophils. The experiments were performed at both
37°C and at 0°C. The ability of eosinophils to form
rosettes with both EA^ab and EA^ab is shown in Fig. 8.
Using either temperatures there was no rosette formation
by eosinophils and EA^ . In contrast, eosinophils formed
Y»p K
rosettes with EA„ at both temperatures, although rosette
VJ
formation at 0°C was significantly greater. Similarly,
in all experiments neutrophils formed rosettes with EA^
but not with EAj^a*).
It was concluded that, under the experimental
conditions used, there were no receptors for rabbit IgM on
human eosinophils or neutrophils and, therefore, red cells
sensitized with rabbit IgM were used for the preparation
of complement coated intermediates so that when testing for
rosette formation with various complement components, there
was no possibility that the rosettes which formed were due
to the presence of IgM receptors.
3.2 Eosinophil and neutrophil rosettes with untreated
sheep red cells
Unsensitized sheep red cells were tested for their
capacity to form rosettes with eosinophils, neutrophils and
lymphocytes under the experimental conditions described.

















Rosette formation "by human eosinophils with untreated
sheep red cells (E), EAga^ and EA^aD.
The bars represent the mean (±1 S.D.) of five
experiments.
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with untreated sheep red cells whilst neither eosinophils
nor neutrophils showed any significant rosette formation
(Fig. 9). The mean (± 1 S.D.) percentage rosettes was
46.0 ± 5.5 for lymphocytes, 6.0 ± 2.0 for neutrophils and
7.0 ± 2.5 for eosinophils.
3.3 Eosinophil and neutrophil rosettes with AET-treated
sheep red cells
The rosettes formed between T lymphocytes and untreated
sheep red blood cells are known to be fragile and can easily
break. Therefore, several possible methods for stabilizing
the red cell binding have been described. One of these
methods involves the treatment of the sheep red cells with
aminoethylisothiouronium bromide hydrobromide (AET) which
has been reported to enhance markedly their T cell binding
capacity (Kaplan and Clark, 1974).
When sheep red cells were treated with AET and then
tested for E rosette formation with human eosinophils and
neutrophils there was no difference between their ability
to form rosettes before and after treatment (Fig. 9). The
mean (± 1 S.D.) E (AET-treated) percentage rosettes was
8.0 ± 3.0 for neutrophils and 6.5 ± 3.0 for eosinophils.
With lymphocytes after AET treatment the mean (± 1 S.D.)
percentage E rosettes was 58.5 ± 5.0.
Therefore, although the AET treatment of sheep red
blood cells markedly enhanced their lymphocyte binding,
it had no effect on rosette formation by either the




B AET treated Sheep red cellsUntreated Sheep red cells
Eosinophils Neutrophils Lymphocytes
Ei&i 9
Rosette formation by human eosinophils, neutrophils and
lymphocytes with AET-treated sheep red cells and with untreated
sheep red cells.
The bars represent the mean (+ 1 S.D.) of seven
experiments.
4.0 SUMMARY
Human eosinophils and neutrophils formed rosettes with
EAq . Rosette formation was directly related to the amount
of sensitizing antibody and was inhibited by heat aggregated
human IgG.
Receptors for human IgG on human eosinophils and
neutrophils were also demonstrated by using heat aggregated
human IgG and fluorescent-labelled anti-human IgG.
Under the experimental conditions described in this
study, no rosette formation could be demonstrated between
human eosinophils and neutrophils with either (i) human red
cells (0 or ® R2R2^ sensitized with various sources of
anti-D, (ii) sheep red cells sensitized with rabbit IgM
"V» o Vv
(EA^j ), (iii) untreated sheep red cells, or (iv) sheep
red cells treated with AET.
There was no significant difference in the percentage
of eosinophils or neutrophils forming rosettes with EA^
when cells from patients with eosinophilia of various
aetiology were compared to cells from healthy individuals.
SECTION II - DETECTION OF RECEPTORS FOR VARIOUS
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1.0 DETERMINATION OF OPTIMAL EXPERIMENTAL CONDITIONS
1.1 Time course and temperature
i*3b
Sheep red cells sensitized with rabbit IgM (EA^ )
rab
were used in these experiments. EA^ coated with purified
human CI (EAC1) did not form rosettes with either eosinophils
or neutrophils at either 0°C or 37°C. When purified human
C4 was added to EAC1 to form EAC14 intermediate^ rosette
formation with both eosinophils and neutrophils was observed.
When C2 was added to EAC14 to form EAC142, no rosettes were
detected. With the addition of C3 to EAC142 to form EAC1423,
rosette formation was again detected with both eosinophils
and neutrophils. From these preliminary experiments it was
concluded that neutrophils and eosinophils can form rosettes
only with EAC14 and EAC1423 cells. It was, therefore,
decided that the optimal experimental conditions for EAC14
and EAC1423 rosette formation by eosinophils and neutrophils
should be determined.
The indicator red cells, i.e. EAC14 and EAC1423, were
tested for rosette formation by eosinophils and neutrophils
at 0°C, room temperature and at 37°C at various incubation
times. For both intermediates it was found that the rosettes
were better expressed at 37°C than at room temperature or at
0°C (Figs. 10, 11, 12 and 13). In addition, it was found
that there was a time-dependent increase in the rosette
formation by both eosinophils and neutrophils with EAC14 and
EAC1423 up to 30 min after which the percentage of rosettes
remained relatively constant (Figs. 10, 11, 12 and 13). It









The effect of variation of temperature and time of
incubation on EAC14 rosette formation by human neutrophils.





















The effect of variation of temperature and time of
incubation on EAC14 rosette formation by human eosinophils.
The points represent the mean (± 1 S.D.) of five
experiments.
Fig. 12
The effect of variation of temperature and time of
incubation on EAC3b rosette formation by human neutrophils.
The points represent the mean of two experiments.
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Fig. 13
The effect of variation of temperature and time of
incubation on EAC3b rosette formation by human eosinophils.
The points represent the mean of two experiments.
at 37°C as optimal conditions for the detection of




2.0 DEPENDENCE OF HUMAN GRANULOCYTE COMPLEMENT ROSETTES
ON INCREASING CONCENTRATIONS OF C4 AND C3
As shown in Fig. 14 and Fig. 15, EAC14 and EAC1423
rosette formation by human eosinophils and neutrophils was
directly related to the input of C4 or C3. Increasing
amounts of these purified complement components resulted in
increased numbers of eosinophil rosettes which paralleled
the percentage of lysis obtained following the addition of
the appropriate late components required to complete the
haemolytic sequence. Similar results were obtained with
neutrophils (not shown) although the percentage of rosetting
cells was approximately two times greater. Therefore, the
ability of eosinophils and neutrophils to recognise activated
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Fig. 14
The effect of increasing concentrations of human C4 on
EAC14 eosinophil rosette formation and lysis with terminal
human complement components (C2-C9).
The points represent the mean (± 1 S.D.) of five
experiments.
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Fig. 15
The effect of increasing concentrations of human C3 on
EAC3b eosinophil rosette formation and lysis with terminal
human complement components (C5-C9).














3-° INHIBITION OF C4 ROSETTE FORMATION BY PURIFIED C2
It was observed during the course of these experiments
that EAC142 cells did not form rosettes with either eosinophils
or neutrophils. Knowing that C2 is a labile component, it
was decided that this finding should be investigated in
greater depth. In five experiments (Table I) it was found
that C2 inhibited C4 rosette formation provided that the
incubation was done at 0°C so as not to allow the C2 to decay.
Binding of EAC14 to the eosinophils and neutrophils can be
restored by allowing C2 decay from EAC142 cells after
incubation of EAC142 at 37°C for 30 min, and the EAC142
can be shown to be in an EAC14 state since they can be
agglutinated by monospecific anti-human C4. To show that
the inhibition of EAC14 rosette formation was due to the
bound C2 and not to the presence of C3b inactivator, which
can also inactivate C4, the C2 preparation was assayed for
the presence of C3b inactivator. It was found to be
completely free from this enzyme. From these C2 decay
experiments it was concluded that the addition of C2 to




The effect of C2 decay on the binding of EAC142
with human eosinophils and neutrophils.





















4.0 ROSETTE FORMATION BETWEEN EOSINOPHILS AND NEUTROPHILS
AND EAC1423d
C3d coated red cells were prepared by treating EAC1423b
cells with purified human C3b inactivator (KAF) for 1 hr at
37°C. These cells were referred to as C3d cells because
they were, in contrast to the untreated C3b cells, no
longer immune adherence positive, could not be lysed by the
addition of C5-C9 and were more agglutinable by monospecific
anti-C3d. It is now believed that the steps involved in
the breakdown of C3b by the C3b inactivator are more complex
(Harrison and Lachmann, 1978) (see Discussion).
Both EAC1423b and EAC1423d cells formed rosettes with
eosinophils and neutrophils (Table II). However, the
percentage of eosinophil C3d rosettes was significantly
less than that for eosinophil C3b rosettes (p <0.05).
There was no difference between the percentage of C3b and
C3d rosettes formed by neutrophils.
The percentage of eosinophils and neutrophils, from
patients with eosinophilia, forming rosettes with EAC3d was
similar when compared to cells from healthy individuals.
Unfortunately only neutrophils and eosinophils from four
individuals were tested for their capacity to form EAC3d
rosettes (Table II).
Plate IV
Eosinophil rosette formation with EAC3d
(May-Grunwald/Giemsa, x 1000 magnification)
TABLE II
Eosinophil and neutrophil rosettes with EAC3b and
EAC3d.
Both EAC3b and EAC3d were prepared with 400 effective


































































































5.° COMPARISON BETWEEN EOSINOPHILS AND NEUTROPHILS FROM
PATIENTS WITH EOSINOPHIL!A AND THOSE FROM HEALTHY DONORS
The percentages of eosinophils and neutrophils from
15 healthy individuals and 15 patients with eosinophilia of
various aetiology forming rosettes with EAC14 or EAC1423 are
shown in Fig. 7 and in Table V. The percentage of eosinophil
rosettes with EAC14 or EAC1423 was significantly lower (p <0.05)
in the eosinophilic patients. When the neutrophils from the
same patients were compared with neutrophils from the same 15
healthy donors, there was no significant difference in the
percentage of rosetting cells with EAC14 or EAC1423 (Fig. 7).
i*3. Id
As with EA^, rosettes, the percentage of blood eosinophilia
and the percentage of rosetting eosinophils or neutrophils
with EAC14 or EAC1423 in 15 eosinophilic patients were unrelated
to the various disease states (Table V).
6.0 SUMMARY
The capacity of sheep red cells (E) coated with
various purified human complement components to form
rosettes with human neutrophils and eosinophils has been
studied. The results are summarized in Table III.
Untreated sheep red cells (E), E sensitized with rabbit
IgM (EA^ab), EAC1 and EAC142 did not form rosettes with
either neutrophils or eosinophils when tested at 0°C or
at 37°C. The apparent rosette formation by EAC142
with both neutrophils and eosinophils at 37°C (shown in
parenthesis in Table III) was thought to be due to C2 decay
since the intermediate can then be shown to be in an EAC14
state rather than an EAC142 state as determined both
antigenically and by haemolytic tests.
EAC14 (prepared with 4000 effective molecules of
human C4 per red cell), EAC1423b and EAC1423d (both
prepared with limited amounts of C4) formed rosettes with
eosinophils and neutrophils. The rosette formation with
both C3b and C3d was not tested at 0°C because it was shown
from early experiments that complement rosettes are better
expressed at 37°C.
Sheep red cells sensitized with rabbit IgG (EA^ )
formed rosettes with both eosinophils and neutrophils which,
in contrast to complement rosettes, were better demonstrated
at 0°C.
From these results it was concluded that human
eosinophils and neutrophils bear membrane surface receptors
for the human complement components C4, C3b and C3d. By
decay experiments it was concluded that C2, in addition to
TABLE III
Eosinophil and neutrophil rosettes with untreated
sheep red cells (E) or with E coated with antibody and
various human complement intermediates.
The figures represent the mean values of 15 experiments
(± 1 S.D.) with the exception of the C3d experiments which
were performed eight times.
Rosette formation by EAC142 at 37°C was thought to
represent EAC14 rosettes as a result of C2 decay and is,
therefore, recorded in parenthesis.
EAC14 and EAC142 were prepared with 4000 effective
molecules of C4 per cell.
EAC3b and EAC3d intermediates were prepared with
400 effective molecules of C4 per cell.






















































































































































































































































































































































































































forming the classical pathway convertase with CI and C4,
inhibited eosinophil and neutrophil rosette formation with
EAC14.
The percentage of eosinophils forming rosettes with
EAC14 or EAC1423 was significantly reduced in patients with
eosinophilia of various aetiology when compared to eosinophils
from controls. When neutrophils from the same eosinophilic
patients were compared to controls in terms of the percentage
of EAC14 or EAC1423 rosettes, there was no significant
difference.
These results, taken together with the previously
known findings on the human monocyte, suggest that all
circulating human phagocytic cells may have similar membrane
receptors for promoting adherence of opsonized particles and
that with eosinophils the numbers of complement receptors
may be altered in disease.
SECTION III - ENHANCEMENT OF HUMAN EOSINOPHIL
COMPLEMENT RECEPTORS BY PHARMACOLOGICAL MEDIATORS
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An increase in the number of eosinophils, both in
the tissues and circulation, is a characteristic feature
of various clinical conditions of which common examples are
diseases associated with immediate-type hypersensitivity.
A considerable amount of information is now available on
various mechanisms by which eosinophils accumulate at the
site of allergic tissue reactions. For instance, various
products of the anaphylactic reaction are preferentially
chemotactic for eosinophils in vitro. These include the
eosinophil chemotactic factor of anaphylaxis (ECF-A) (Kay
and Austen, 1971), now chemically characterised as two
closely related acidic tetrapeptides (Val-Gly-Ser-Glu and
Ala-Gly-Ser-Glu) (Goetzl and Austen, 1975), histamine
(Clark ejfc al, 1975; Turnbull and Kay, 1976) and one of
its major catabolites, imidazoleacetic acid (Turnbull and
Kay, 1976).
At the present time, the exact mechanism by which
eosinophils respond to these agents which cause random or
directional motility is not clear although the participation
of 'recognition units® present on the cell membrane has been
suggested. It was proposed that the ECF-A peptides may
interact with the eosinophil cell membrane through a receptor
which has both a hydrophobic and ionic domain and to which
the serine hydroxyl group of the valyl- or alanyl-peptide
could attach by hydrogen bonding (Goetzl and Austen, 1976).
In the earlier sections of this thesis the eosinophil cell
membrane was shown to bear receptors for IgG and various
complement components, C4, C3b and C3d. The relationship
124
between these receptors and those proposed for various
chemotactic factors is unknown. Since the anaphylaxis-
associated agents, such as ECF-A and histamine, are
preferentially chemotactic for eosinophils, experiments
described in this section were performed to see whether
the pharmacological mediators of anaphylaxis have a direct
effect on the eosinophil cell membrane, as assessed by
their capacity to alter the expression of either IgG or
complement receptors.
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2.0 EFFECT OF INCREASING CONCENTRATIONS OF THE ECF-A
PEPTIDES AND HISTAMINE
2.1 Effect on C3b and IgG receptors
In these experiments the leucocyte suspensions were
incubated with increasing concentrations of the two ECF-A
peptides or histamine (5 x 10~^, 5 x 10~® and 5 x 10-^ mol.l-"'"),
and they were added to the indicator sheep red cells to test
their rosette forming capacity (see Materials and Methods).
With increasing concentrations of the valyl-, alanyl-peptide
or histamine there was a dose-dependent increase in the
percentage of eosinophils, but not of neutrophils, which
formed rosettes with EAC3b (Fig. 16). There was no increase
in the percentage of eosinophils or neutrophils forming
rosettes with EA^ . Increasing concentrations of the
valyl- or alanyl-peptide or histamine did not increase the
percentage of monocyte EAC3b or EA^ rosettes.
Further experiments were performed where eosinophils,
neutrophils and monocytes were incubated with increasing
concentrations of the peptides and histamine and then added
to sheep red cells prepared with two doses of C3 (1000 and
2500 effective molecules per cell). The aim of these
experiments was to exclude the possibility that by using a
high dose of C3 on the indicator red cells (2500 molecules
per cell), the neutrophils and monocytes, having more avid
receptors for C3b, may express the maximum rosette formation
and hence make the detection of any enhancement impossible.
Dose-dependent enhancement of eosinophil rosette formation
was observed with both doses of C3. The mean percentage
126
Fig. 16
The effect of increasing concentrations of the valyl- (9)
and alanyl- (0) ECF-A peptides and histamine (A) on EAC3b and
EAjE3-*5 rosette formation by human eosinophils and neutrophils.
The lines represent the percentage rosettes of untreated
eosinophils and neutrophils.
Each point represents the mean (± 1 S.D.) of five
experiments.
127
enhancement for EAC3b (containing 2500 effective C3
molecules/cell) rosettes at the highest concentration
tested was 78% for the valyl-, 88% for the alanyl-peptide
and 83% for histamine. When EAC3b cells containing less
C3, i.e. 1000 effective molecules/cell, were used (so
lowering the baseline percentage of rosettes) the percentage
enhancement was 80%, 59% and 75% for the valyl-, alanyl-
peptide and histamine respectively (Table VI). In contrast,
neither ECF-A peptides nor histamine had any apparent effect
on C3b rosette formation by neutrophils or monocytes,
irrespective of whether the higher or lower dose of C3 per
indicator red cell was used (Table VI).
In another series of experiments (not shown) the
sensitizing IgG titre was lowered to give less neutrophil
rak
or monocyte EA^ rosettes. Using these indicator red cells
I*clTD
there was still no enhancement of EA^ rosettes on either
neutrophils or monocytes following their incubation with
increasing concentrations of the peptides or histamine.
2.2 Effect on C4 and C3d receptors
Human eosinophils and neutrophils were shown to have
membrane receptors for C4 and C3d (Section II). The effect
of increasing concentrations of the ECF-A peptides and
histamine on the C4 and C3d eosinophil receptors was also
tested using sheep red cells coated with human C4 (EAC14)
or with C3d (EAC1423d).
With increasing concentrations of either the valyl-,
alanyl-peptide or histamine there was a dose-dependent
increase in the enhancement of the EAC14 rosettes (Figs.
17a, 17b, 17c) which was very similar to the effect seen with
TABLE VI
The effect of the ECF-A tetrapeptides (Val-Gly-Ser-Glu
and Ala-Gly-Ser-Glu) and histamine on the percentage of
eosinophil, neutrophil and monocyte EAC3b rosettes using
EAC3b cells prepared with two concentrations of C3. The
percentage enhancement is shown in parenthesis.
The figures represent the mean (± 1 S.D.) of five
experiments (for monocytes tested with EAC3b prepared with
























































































































































































































































































EAC3b rosettes. The mean percentage enhancement for EAC14
rosettes, at the highest concentration tested, was 70 ± 8%
for the valyl- and 71 ± 6% for the alanyl-peptide (Figs. 17a,
17b). With histamine the mean percentage enhancement for C4
rosettes was 65 ± 10% when tested at the highest dose (Fig. 17c).
In contrast, the mean percentage enhancement for C3d rosettes
using the same concentration of these agents was 18 ± 7% for
the valyl-, 21 ± 8% for the alanyl-peptide and 17 ± 7% for
histamine (Figs. 17a, 17b, 17c). These values represented
an absolute increase from 28 ± 6% rosettes for the untreated
controls to 33 ± 8% for the valyl-, 34 ± 6% for the alanyl-















































The effect of increasing concentrations of the valyl
peptide on eosinophil rosette formation with EAC3b, EAC14
EAC3d and EA^ab
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Fig. 17(b)
The effect of increasing concentrations of the alanyl
peptide on eosinophil rosette formation with EAC3b, EAC14,
EAC3d and EA£ab.










































The effect of increasing concentrations of histamine on
eosinophil rosette formation with EAC3b, EAC14, EAC3d and
EA-b
The bars represent the mean (± 1 S.D.) of five
experiments.
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3.0 TIME-COURSE OF EOSINOPHIL COMPLEMENT RECEPTOR
ENHANCEMENT
The enhancement of the eosinophil EAC3b rosette
formation by both the ECF-A peptides or histamine was found
to be time-dependent (Fig. 18). With the increase in the
incubation time there was a corresponding linear increase
in rosette formation by the valyl- and alanyl-peptide for
the first 40 min after which their effect seemed to plateau.
In contrast, the effect of histamine seemed to be delayed;
most of the histamine-induced rosette enhancement occurring
between 40 and 80 min.
The enhancement of EAC14 eosinophil rosettes by the
ECF-A peptides with time gave virtually identical results
to those observed for EAC3b. However, with histamine the
enhancement of eosinophil EAC14 rosettes was similar to that
observed with the ECF-A peptides, i.e. most of the increase
being observed by 40 min (Fig. 19).
In subsequent experiments the time used to detect
EAC3b and EAC14 eosinophil complement receptor enhancement
was 60 min, i.e. well after the response had plateaued.
With C3d even when the incubation time was increased
up to 180 min, no further increase was noticed in C3d
eosinophil rosettes (Fig. 20). Similarly, there was no
increase in IgG eosinophil rosettes following the incubation
of the eosinophils with either of the ECF-A peptides or
histamine for up to 3 hr.
In all these time-course experiments mentioned above
the ECF-A peptides and histamine were tested at the highest
— 5






















The effect of time on enhancement of EAC3b rosette
formation by eosinophils and neutrophils following incubation
with the valyl- (&) and alanyl- (O) ECF-A peptides and
histamine (A).
Each mediator was tested at a concentration of 5 x 10
mol.l~x.
-5
The lines represent the percentage of rosettes of untreated
eosinophils and neutrophils.






The effect of time on enhancement of EAC14 rosette
formation by human eosinophils and neutrophils following
incubation with the valyl- (€>) and alanyl- (A) ECF-A peptides
and histamine (0).
_ 5
The mediators were tested at a concentration of 5 x 10
rnol. l--^.
The lines represent the percentage of rosettes of
untreated eosinophils or neutrophils.






The effect of time on enhancement of EAC3d rosette
formation by human eosinophils and neutrophils following
incubation with the valyl- (A) and alanyl- (0) ECF-A peptides
and histamine (O).
The three mediators were tested at a concentration of
5 x 10-5 mol.l--*-.
The lines represent the percentage of rosettes of
untreated eosinophils or neutrophils.
Each point represents the mean of two experiments.
138
4.0 EFFECTS OF VARIOUS PRODUCTS OF THE ANAPHYLACTIC
REACTION ON EOSINOPHIL COMPLEMENT RECEPTOR ENHANCEMENT
4.1 Effect of ^on-chemotactic* mediators
Together with histamine and ECF-A other mediators are
known to be released during the anaphylactic reaction.
These include bradykinin, 5-hydroxytryptamine and the
prostaglandins PGE^, Eg and Fga. Experiments were performed
in which these pharmacological mediators were incubated at
-5 -7
comparable concentrations (5 x 10 to 5 x 10 mol/1) to
those used for the ECF-A peptides or histamine to assess
their effects on eosinophil C3b rosette forming capacity
(Fig. 21). No significant enhancement was observed with
bradykinin, PGE^, PGEg or PGFg^. However, with 5-
hydroxytryptamine an enhancement of 25 ± 2.6% was observed
—5
but only at the highest concentration tested (5 x 10 mol/1).
The enhancement of histamine or with the ECF-A peptides was
almost three times this value.
4.2 Effect of a human anaphylactic lung diffusate
A human lung anaphylactic diffusate (containing a final
histamine concentration of 8.1 x 10~ mol/1) gave an enhance¬
ment of C3b rosettes in a dose-dependent fashion (Fig. 21).
The appropriate controls, i.e. diffusates from unsensitized
lung challenged with the antigen (TGP) or sensitized lung
fragments incubated only with Tyrode's buffer, gave no
significant enhancement. A 1 in 10 dilution of the
anaphylactic diffusate (containing a final histamine con-
_7
centration of 4.05 x 10 mol/1) gave a C3b rosette





































The effect of a human anaphylactic lung diffusate and
various synthetic pharmacological mediators of anaphylaxis
on EAC3b rosette formation by human eosinophils.
The bars represent the mean (± 1 S.D.) of five
experiments (with the exception of the diffusate and
bradykinin - three experiments).
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comparable enhancement was only achieved with a dose of
—6
5 x 10" mol/1, that is about ten times more histamine than
that contained in the anaphylactic diffusate.
4.3 Effect of mixtures of ECF-A peptides and histamine
on eosinophil complement receptor enhancement
Since the anaphylactic lung diffusate is known to
contain the ECF-A tetrapeptides in addition to histamine and
other pharmacological mediators, experiments were performed
to see whether there was an additive or synergistic effect,
in terms of complement receptor enhancement, when synthetic
peptides and histamine were mixed in various combinations.
_5
When 5 x 10 mol/1 of valyl- or alanyl-peptide were mixed
-5 -7
with histamine over the dose range 5 x 10 to 5 x 10 mol/1
the final enhancement of the eosinophil C3b rosettes was
either slightly (but insignificantly) greater, or the same
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Val - Gly - Ser - Glu
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Fig. 22(a)
The_effect of^mixing histamine at two concentrations
(5 x 10~°, 5 x 10"' mol.l"-*-) with increasing concentrations
of the valyl-peptide on the enhancement of EAC3b rosette
formation by human eosinophils.
The lines represent the percentage of rosettes with
untreated eosinophils.
The points represent the mean of two experiments.
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Concentration (M.L-1) Concentration (M.L-1)
Fig. 22(b)
The effect of mixing histamine at two concentrations
(5 x 10-5, 5 x 10~7 mol.1-1) with increasing concentrations
of the alanyl-peptide on the enhancement of EAC3b rosette
formation by human eosinophils.
The lines represent the percentage of rosettes with
untreated eosinophils.
The points represent the mean of two experiments.
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5.0 EFFECT OF A HISTAMINE PRECURSOR (HISTIDINE) AND
SOME MAJOR HISTAMINE CATABQLITES ON EOSINOPHIL COMPLEMENT
RECEPTOR ENHANCEMENT
L-histidine (a histamine precursor) and some of its
major catabolites (imidazoleacetic acid (ImAA), 1,4-
methylhistamine (1,4-MeHm), 1,4-methyl-imidazoleacetic
acid (1,4-MeImAA) and N-acetylhistamine (N-AcHm)) were
tested, at comparable concentrations to those used for the
ECF-A tetrapeptides or histamine, for C3b receptor enhancing
activity. It can be seen from Fig. 20 that enhancement of
eosinophil C3b rosettes was only observed with imidazole¬
acetic acid, which has previously been reported to be a
selective chemoattractant for human eosinophils. The
enhancement produced by ImAA was similar to that for
histamine in terms of the concentrations used and also in
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The effect of various concentrations of histamine,
L-histidine and the major histamine catabolites on eosinophil
EACSb rosette formation.




The ECF-A tetrapeptides (Val-Gly-Ser-Glu and Ala-Gly-
Ser-Glu) and histamine markedly enhanced the expression of
human eosinophil receptors for C3b. The enhancement was
both dose- and time-dependent, and highly selective for the
eosinophil since there was no evidence that C3b receptors
on neutrophils or monocytes were altered by these pharma¬
cological agents even when varying concentrations of C3 were
added to the indicator red cells.
The agents similarly enhanced receptors for C4 but
under the same conditions C3d and IgG receptors were
unaffected.
A number of other pharmacological mediators including
bradykinin, and the prostaglandins PGE^, E2 and Fgg, had no
apparent effect on eosinophil C3b receptors at the same
-5 -7
molar concentrations (5 x 10 to 5 x 10 mol/1).
However, a major histamine catabolite, imidazoleacetic
acid, also recognised as an anaphylaxis-associated
eosinophilotactic agent, enhanced eosinophil C3b receptors
to a degree comparable to that of histamine. In contrast,
L-histidine and the histamine catabolites, N-acetylhistamine,
1,4-methylhistamine and l-methyl-4-imidazoleacetic acid, had
no eosinophil C3b enhancing effect. 5-hydroxytryptamine,
-5
at the highest concentration tested (5 x 10 mol/1), gave
enhancement of eosinophil C3b receptors which was approxi¬
mately one-third of that achieved with the same concentration
of the ECF-A peptides, histamine or imidazoleacetic acid.
A human lung anaphylactic diffusate also enhanced
eosinophil C3b receptors. Approximately ten times more
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synthetic histamine than that contained in the lung-derived
material was required for comparable enhancement indicating
that the histamine and ECF-A peptides present in the
diffusate may have combined to give an optimal enhancing
effect. However, when synthetic histamine and the valyl-
or alanyl-peptide were mixed in various proportions, the
enhancing effect was no greater than that achieved when each
agent was tested alone.
These results may suggest that pharmacological
mediators of hypersensitivity may regulate certain eosinophil-
dependent biological reactions and that there may be a
direct relationship between the eosinophil surface Recogni¬
tion unit* for eosinophil migration and some of the membrane




SECTION IV - THE PARTICIPATION OF ANTIBODY AND/OR
COMPLEMENT IN EOSINOPHIL-DEPENDENT KILLING OF
SCHISTOSOMULA OF SCHISTOSOMA MANSONI
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1.0 INTRODUCTION
For many years an association between helminth infection
and increased levels of peripheral blood and tissue eosinophils
has been recognised. In human disease this association is
particularly marked in patients with filariasis, schistoso¬
miasis, ascariasis, trichinosis and visceral larva migrans.
In addition, tropical pulmonary eosinophilia is now believed
to be associated with cryptic filarial infections (Neva et al,
1975). In animals infected with helminths such as Fasciola
hepatica and Oesophagostomum radiatum high levels of blood
eosinophils are also a common finding. In experimental
animals infection with Trichinella spiralis is one of the
most reliable sources of inducing a peripheral blood
eosinophilia.
In spite of this consistent and striking relationship
between eosinophilia and helminth infection, it was not easy
to attribute a specific functional role to the eosinophil in
such situations. However, more recently several workers
have described various in vitro and in vivo cell-mediated
effector systems in which eosinophils and other leucocytes
may be involved in limiting the effects of helminth
infections. Dean et al (1974) demonstrated a complement-
dependent IgG antibody in immune rats and guinea pigs
(1975) which would rapidly cause damage to the larval stage
(schistosomulum) of Schistosoma mansoni in the presence of
neutrophils in vitro. This damage was associated with
discharge of neutrophil enzymes on to the surface of the
organisms.
In 1974 Perez described a macrophage-dependent reaction
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capable of damaging schistosomula which was dependent on a
heat-stable cytophilic IgG antibody which confers on
macrophages the ability to adhere and kill schistosomula.
Capron et al (1975) described another macrophage-dependent
system in which normal rat macrophages can adhere and kill
schistosomula if they were preincubated with a heat-labile
factor in immune rat serum. This factor was later found
to be an IgE antibody.
More recently the human eosinophil was shown to mediate
antibody-dependent damage of schistosomula of Schistosoma
mansoni in vitro (Butterworth et al, 1975). In this system
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larval damage was measured by the release of chromium from
pre-labelled schistosomula and the antibody involved was
shown to be IgG (Butterworth et al, 1977b). Similar antibody-
dependent eosinophil damage to schistosomula has subsequently
been described in the baboon (Butterworth ejt al, 1976) and in
rat (Mackenzie et al, 1977).
In 1973 Ramalho-Pintc et al found that schistosomula
can be coated with C3 in the absence of antibody through the
activation, by the tegument, of the alternate pathway of the
complement system following their incubation with fresh rat
serum. These schistosomula, coated with C3, were shown to
be more susceptible to damage by rat eosinophils than IgG
coated organisms.
The experiments described in this section were designed
to study the capacity of the human eosinophil to mediate
damage to schistosomula coated with antibody and/or complement.
Also, since rat neutrophils and macrophages were previously
implicated in damage to schistosomula, human neutrophils and
mononuclear leucocytes were compared with eosinophils in
terms of their capacity to kill schistosomula. Other
experiments were performed to see whether schistosomula
can activate human complement by the alternate pathway.
Also the role played by combining both human antibody and
complement in schistosomula damage by various human
leucocytes, which is presumably more relevant to the
in vivo situation, was assessed.
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2.0 THE ROLE OF ANTIBODY AND/OR COMPLEMENT
In the eight experiments shown in Table VII
granulocyte preparations obtained from eight eosinophilic
patients were tested for their capacity to mediate
schistosomula (Sch) damage in three different experimental
systems, i.e. antibody alone (Ab), complement alone (C),
and a combination of antibody and complement (Ab + C).
The granulocyte preparations (G) contained only eosinophils
or neutrophils, contamination by other cell types being
less than 3%. Also, mononuclear cells (M) from the same
patients were examined as regards their capacity to cause
schistosomula damage in the three different systems. With
granulocytes, killing with antibody alone (Sch + Ab + G)
was approximately two and one half times greater than the
appropriate control (Sch + G). Granulocyte killing of
schistosomula coated with complement via the alternate
pathway activation (Sch + C + G) was about four times
greater than the appropriate control (Sch + C + G) and
about two times greater than killing with antibody alone.
However, it is clear from this table that the most
efficient system, under these experimental conditions, was
the combination of antibody and complement (Sch + Ab + C + G).
The relative efficiencies of the three systems expressed in
terms of the mean ± 1 S0D. percentage killing for the eight
experiments shown were 70 ± 8 for Sch +Ab+C+G, 52 ±9
for Sch + G + G and 31 ± 7 for Sch + Ab + G.
From these experiments there was no evidence that there
was an association between the percentage of eosinophils in
the granulocyte cell suspensions and the magnitude of the
damage to the schistosomula.
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Plate V
Adherence of granulocytes to schistosomula coated





Granulocyte adherence and killing of schistosomula
coated with complement. Note the damaged tegument
on one side of the worm,
(x 400 magnification)
TABLE VII
Killing of schistosomula (Sch) coated with antibody
alone 'Ab alone', complement alone 'C alone' and antibody +
complement 'Ab + C' by: (a) granulocytes (G) of varying
eosinophil concentrations, (b) mononuclear leucocytes (M).
The figures represent the percentage killing for each
duplicate well.
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Damage of schistosomula by mononuclear cells was
significantly lower (p <0.001) in all three systems when
compared to equivalent damage by granulocytes (Table VII),
although it remained markedly higher than the appropriate
control. The mean ± 1 S.D. percentage killing by mono¬
nuclear cells was 37 ± 4 for Sch + Ab + C, 31 ± 5 for
Sch + C, and 22 ± 3 for Sch + Ab.
2.1 Effect of increasing concentrations of antibody
and complement
When various dilutions of fresh normal human serum
(as a source of complement) were used, the percentage of
schistosomula killed both in the Ab + C system (using a
constant amount of antibody) and with *C alone*, was
directly related to the concentration of the serum used.
Similarly, dilutions of human anti-schistosomiasis serum
used in the *Ab alone* system resulted in a decrease in
the percentage of schistosomula killed (Fig. 24).
Essentially the same results were found with the mononuclear
cells.
2.2 Participation of purified human IgG
Human IgG was purified from whole anti-schistosomiasis
serum by ion exchange chromatography on a DE-52 column (see
Methods). In two different experiments illustrated in Fig. 25
it was shown that when this purified IgG was used instead of
the whole antiserum there was very little difference in terms
of the percentage of schistosomula killing in both the *Ab
alone* and the *Ab + C* systems. These results suggested
that IgG might have accounted for virtually all the activity
Fig. 24
The effect of varying the concentrations of antibody
or complement on the granulocyte killing of schistosomula
coated with antibody and/or complememt.
The points represent the mean (± 1 S.D.) of four
experiments.
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present in the anti-schistosomiasis serum. Further evidence
was obtained when a fraction eluted from the DE-52, which
contained no IgG but an equivalent amount of IgA and IgM
to those present in the whole anti-schistosomiasis serum,
was tested for its capacity to damage schistosomula, and
shown to give a percentage killing no greater than that
obtained with controls (Fig. 25).
2.3 (a) Participation of the classical pathway of the
complement system
In these experiments human purified complement
components were used. To sensitized schistosomula (SchA)
the early classical complement components, i.e. CI, C4, C2
and C3, were added sequentially to form SchAC1423. The
presence of schistosomula-bound C3 was confirmed directly
by immunofluorescence using fluorescein-labelled anti-human
C3 (Table VIII). The Sch AC1423 were found to be susceptible
to granulocyte killing. Furthermore, the addition of C3 to
SchAC142 resulted in a proportional increase in the percentage
killing of schistosomula by granulocytes which was directly
related to the number of effective molecules of C3 added per
schistosomulum (Fig. 26). However, schistosomula coated
with (1) antibody alone (SchA), (2) CI and C4 (SchAC14) or
(3) CI, C4 and C2 (SchAC142), were all equally susceptible
to killing by granulocytes.
2.3 (b) Participation of the alternate pathway of the
complement system
Following the incubation of schistosomula with fresh
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Fig. 25
The effect of fractionated IgG and unfractionated (Ab)
anti-schistosomula sera on schistosomula killing, with or
without complement, by granulocyte suspensions containing
increasing eosinophil concentrations.
The effect of DE-52 fraction containing an equivalent
amount of IgA and IgM to that present in the unfractionated
serum is also shown.


















Sch SchA SchAC14 SchAC142 SchAC1423 SchAC1423 SchAC1423 SchAC1423
Fig. 26
The killing of sehistosomula (Sch) coated with human
anti-schistosomula serum (A) and purified components of the
classical pathway of human complement.
Increasing concentrations of purified human C3 were added
to SchAC142 (to the right of the interrupted line).
The columns represent the mean of three experiments.
Plate VII
Fluorescence of schistosomula coated with
(through classical pathway activation, i.e
sensitized schistosomula + C1423) in the
presence of fluorescent labelled anti-human
(x 400 magnification)
Plate VIII
Fluorescence of schistosomula coated with C3
(through alternate pathway activation) in the
presence of fluorescent labelled anti-human C3.
(x 400 magnification)
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shown to be coated with large amounts of C3 using fluorescent
anti-human C3 (Plate VII). In contrast, there was minimal
fluorescence with fluorescein-labelled anti-human C4.
The capacity of the tegument to bind C3 by alternate
pathway activation was further demonstrated by experiments
using human C2-deficient serum. With this C2-deficient
serum there was a strong fluorescence with anti-human C3
but not with anti-human C4 (Table VIII).
/
Plate IX
Fluorescence of schistosomula (incubated with anti-
schistosomiasis serum and then with fresh normal




Fluorescence of schistosomula treated with antibody
and/or complement in the presence of fluorescent-labelled
anti-human C3 and anti-human C4.
The scoring of fluorescence was from 0 to ++++.

















































3.0 EFFECT OF VARIATION OF EFFECTOR CELL:TARGET RATIO
Experiments were performed to determine the optimum
effector cell:target ratio needed for schistosomula killing
in all three experimental systems using both granulocytes
and mononuclear cells. In all three systems the percentage
killing increased initially with the increase in the number
of leucocytes per schistosomulum (Figs. 27, 28 ). However,
like other killer cell systems previously described, the
degree of killing of the schistosomula seemed to plateau
and remained constant thereafter. In some experiments
(not shown) the ratio was further increased up to 10,000
granulocytes or mononuclear cells per schistosomulum but
the increase in killing was less than 10% than that
achieved with 5,000 leucocytes per schistosomulum.
In all the experiments described in this section
a ratio of 4,000 leucocytes per schistosomulum was used
so as to avoid the difficulty which arises if more cells
are used, e.g. clumping which renders counting of dead
schistosomulum with adherent leucocytes very difficult.
Fig. 27
The effect of varying the ratio of granulocytes:
schistosomula on the killing of schistosomula coated with
antibody (Ab) and/or complement (C).




The effect of varying the ratio of mononuclear cells:
schistosomula on the killing of schistosomula coated with
antibody (Ab) and/or complement (C).
The points represent the mean (± 1 S.D.) of four
experiments (only one experiment was performed for 5 x 10
mononuclear leucocytes/schistosomulum).
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4.0 PREFERENTIAL DAMAGE OF SCHISTOSOMULA BY EOSINOPHILS
Cell suspensions containing only eosinophils and
neutrophils were prepared from the peripheral blood from
each of seven healthy human volunteers. The percentage
of eosinophils in these granulocyte suspensions was varied
from approximately 3-63% and their capacity to kill
schistosomula in the three experimental systems (*Ab alone*,
*C alone1 and *Ab + C*) was examined (Fig. 29). With
cAb alone* the percentage killing ranged between 26 and 36%
and was not affected by varying the ratio of eosinophils to
neutrophils suggesting that the two cell types were equally
effective in mediating schistosomula damage in this system.
In contrast, with *C alone* and *Ab + C*, an increase in the
percentage of eosinophils was associated with a concomitant
increase in the percentage of schistosomula killing which
was highly statistically significant for both systems
(p <0.001) suggesting that preferential killing of
schistosomula by eosinophils can only occur in the presence
of complement. The increase in the percentage killing of
schistosomula by increasing the eosinophil percentage was
observed up to approximately 30% eosinophils, after which
the effect appeared to remain relatively unchanged.
However, the correlation coefficients were calculated for
all the experimental points, i.e. including those points
beyond which the effect appeared to plateau. With eC alone*,
schistosomula killing for the seven experiments shown in
Fig. 29 was in the range of 27 to 40% with neutrophil-rich
(approximately 97%) suspensions to between 45 and 68% with
suspensions rich in eosinophils (approximately 60%).
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EOSINOPHILS {%) EOSINOPHILS (%)
Fig. 29
The effect of increasing the percentage of eosinophils in
the granulocyte suspensions on schistosomula killing using
'Ab alone', ?C alone' of 'Ab + Cf.
Each symbol represents the results obtained from cells
from the same donor studied on the same occasion in each
experimental system. In two experiments only two systems
were studied.
Correlation coefficients were calculated between the
percentage killing and the eosinophil percentage in the donor
granulocyte suspensions. The mean of the r values obtained
in each system were tested for significance against zero using
the Student t-test. The results were as follows:
(i) 'Ab alone' - not significant; (ii) 'C alone' - p <0.001;
(iii) 'Ab + C» - p <0.001.
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Similarly, with the *Ab + C* system killing ranged from
between 37 and 50% to 53 and 82% with the neutrophil-rich
and eosinophil-rich suspensions respectively.
Therefore, it was concluded that both neutrophils
and eosinophils mediate schistosomula damage when complement
is present, either alone or with antibody, but an increase
in damage is demonstrable by increasing the percentage of
eosinophils in the effector cell population.
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5.0 SUMMARY
1. Using an in vitro assay system the capacity of
human eosinophils, neutrophils and mononuclear cells to t
damage the larval stage of Schistosoma mansoni (schistoso-
mulum) was studied. Schistosomula and leucocytes were
incubated either with (i) *antibody alone* (as serum from
patients with schistosomiasis or its IgG fraction or as
baboon anti-schistosomiasis serum), (ii) Complement alone*
or (iii) the combination of antibody and complement.
2. The mean efficiency of killing of schistosomula
by granulocytes, i.e. mixtures of eosinophils and neutrophils,
was 31% for *Ab alone*, 52% for *C alone* and 70% for *Ab + C*;
controls gave 14% killing. Equivalent numbers of mononuclear
leucocytes gave 22%, 31% and 37% killing with *Ab alone*,
*C alone* and *Ab + C* respectively.
3. In all three experimental systems damage of
schistosomula by granulocytes or mononuclear leucocytes was
dependent on the ratio of effector cells to schistosomula.
Furthermore, killing of schistosomula was directly related
to the concentration of the antibody with *Ab alone* and to
the dilution of the complement with *C alone* and *Ab + C*
systems.
4. Granulocyte dependent damage of schistosomula
was directly related to the input of human C3 when the
components of the classical pathway were added sequentially
to schistosomula sensitized with antibody.
5. Increasing the eosinophil percentage in the
granulocyte cell suspension produced no increase in
schistosomula damage in the *antibody alone* system,
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suggesting that under these conditions eosinophils and
neutrophils are equally effective in mediating schistosomula
damage. In contrast, with 'C alone8 and 8Ab + C' an
increase in the percentage of eosinophils was associated
with a concomitant increase in the degree of schistosomula
damage which was highly statistically significant (p <0.001).
6. From these studies it was concluded that under
the appropriate experimental conditions:
(a) damage to schistosomula in. vitro can be
mediated by human eosinophils, neutrophils or
mononuclear leucocytes in the presence of either
8Ab alone8, 8C alone8 or 8Ab + C8.
(b) the efficiencies of the three experimental
systems were Ab + C > C > Ab irrespective of
whether the effector cells were granulocytes or
mononuclear leucocytes.
(c) preferential killing of schistosomula by
human eosinophils, as compared to the neutrophils,
can be demonstrated only when complement is
present in the system either alone or in
combination with antibody.
CHAPTER V - GENERAL DISCUSSION
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1.0 RECEPTORS FOR IgG AND COMPLEMENT ON HUMAN EOSINOPHILS
AND NEUTROPHILS
Using both the rosette technique and immunofluorescence
the presence of receptors for rabbit and human IgG on human
eosinophils and neutrophils was demonstrated. The use of
the rosette technique for the investigation of various cell
membrane markers is well established. In the author's
opinion this technique is easy to perform and relatively
inexpensive. The main practical difficulties were in the
preparation of the fixed slides and the counting procedure.
It was found that the most convenient method for the purpose
of this study was to smear the rosette suspensions on clean
glass slides using a Pasteur pipette allowing the cell
suspension to be drawn by surface tension. The slides were
then dried quickly in air, using either a fan or hair dryer,
fixed in methanol and stained with May Grunwald/Giemsa before
they were counted. The use of wet preparation to count the
rosettes was unsatisfactory because of the considerable
difficulty in differentiating eosinophils rosettes from
neutrophil rosettes, even when phase-contrast microscopy
was used. Again the fixation and staining of the rosette
slides had the advantage of making the preparations semi¬
permanent. This allowed the processing of large numbers
of slides which can be stored for a short time and counted
when convenient. In some early experiments cytocentrifuge
preparations were made but the results were inconsistent,
at least in the author's hands, possibly due to the added
shearing force of the cytocentrifuge, although the rosettes
prepared by this method appeared more impressive.
In counting the rosette slides care must be taken in
selecting suitable fields, particularly with respect to the
ratio and distribution of the indicator sheep red cells to
the leucocytes. Only leucocytes with three or more
adherent indicator red cells were counted as rosettes.
In each slide 200 cells were counted and the numbers of
rosettes were expressed as a percentage of the total number
of cells counted.
In one series of experiments (Fig. 5) a direct immuno-
fluorescent technique was used to demonstrate the presence
of a receptor for human IgG on human eosinophils and
neutrophils. Although it is known that the eosinophil can
show non-specific granular autofluorescence (Fuerst et al,
1965) it was not very difficult to obtain satisfactory
results by using this technique. However, it should be
mentioned that counting of these fluorescing granulocytes
was quite laborious for a method to be recommended for
routine use.
Sheep red cells sensitized with rabbit IgG (EA^a^)
formed rosettes with both human eosinophils and neutrophils
in a dose-dependent fashion using increasing concentrations
of rabbit IgG (Fig. 3). The percentage of neutrophil
rosettes was approximately two and one half times that of
eosinophil rosettes. These results are in agreement with
the previous findings of Tai and Spry (1976) who demonstrated
the presence of receptors for rabbit IgG on eosinophils from
patients with eosinophilia. Messner and Jelinek (1970)
previously described the presence of receptors for human IgG
on human neutrophils using both an in vitro bactericidal-phagocytic
assay and a rosette technique.
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In the present studies experiments were performed to
determine the optimum experimental conditions for detection
of IgG receptors on both neutrophils and eosinophils.
These receptors were better detected at 0°C rather than at
37°C. These results confirmed the previous findings of
Wong and Wilson (1975) who were able to show better
demonstration of IgG rosettes on human neutrophils at 4°C
rather than at 37°C. They have suggested that it is
possible that there might be some shedding of the IgG
receptors at higher temperatures. However, there was no
evidence for shedding of receptors at 37°C in the present
study and the most likely reason for less IgG rosettes at
37°C is the marked degree of phagocytosis observed at this
temperature.
Heat aggregated immunoglobulins possess many of the
properties of antigen-antibody complexes and they appear
to bind to the same membrane receptor sites on various
haemopoietic cells (Dickler, 1974; Dickler and Sachs, 1974;
Hasten et aT, 1975). Therefore, heat aggregated IgG was
used previously by Dickler and Kunkel (1972) to demonstrate
the presence of IgG receptors on human lymphocytes. Others
have also used it to demonstrate the presence of a similar
receptor on human granulocytes (Gupta et al, 1976).
Furthermore, Hallberg (1974) showed that heat aggregated
human IgG could inhibit the in vitro cytotoxic activity of
human lymphocytes for chicken red cells sensitized with
rabbit antibody.
In the experiments described earlier (Chapter IV,
Section I) heat aggregated human IgG was used to detect
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directly the presence of receptors for human IgG (Fig. 5)
or to inhibit the rosette formation by human eosinophils
and neutrophils with sheep red cells sensitized with rabbit
IgG (Fig. 4). The results of these studies taken together
with the results of the experiments in which sheep red cells
sensitized with rabbit IgG (Fig. 3) formed rosettes with
eosinophils and neutrophils, provided strong evidence for
the presence of receptors for human and rabbit IgG on human
eosinophils and neutrophils. The binding between rabbit
or human IgG to the cell membrane of eosinophils and
neutrophils is probably through the Fc region of the IgG,
although during the present work no specific studies were
undertaken to confirm this possibility. Again the sub¬
classes of IgG involved in the binding were not determined,
although Tai and Spry (1976) were able to show that this
receptor on human granulocytes binds to the Fc region of
human IgG^ and IgGg. The demonstration of IgG receptors
on human eosinophils is in agreement with the finding of
Butterworth et al_ (1975) that the human eosinophil is the
principal effector cell which mediates antibody-dependent
killing of schistosomula of Schistosoma mansoni in vitro.
The antibody in this system was identified as IgG
(Butterworth et al, 1977b) and the adherence and killing of
eosinophils to IgG-sensitized schistosomula may be dependent
on the presence of freely available immunoglobulin receptors.
In the present study rosette formation was consistently
detected between EA^, and eosinophils both from healthy
individuals and from patients with eosinophilia (Fig. 7).
These findings were at variance with the report of Tai and
182
Spry (1976) who were unable to demonstrate an appreciable
binding of EA^ with human eosinophils from healthy donors.
It is unlikely that this discrepancy was due to the use of
ox red cells by these workers instead of sheep red cells
which were used in the present study. Differences in the
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preparation of the EAG and the time of incubation allowed
for the rosette formation may provide an explanation for
these differences. Tai and Spry (1976) reported on six
normal individuals using only a four-minute incubation time
whereas in the present study eosinophils from 15 normal
donors were studied using an incubation time of thirty
minutes. In this respect it is also relevant that more
recently the same workers have demonstrated that eosinophils
I*cL1D
from normal donors form EAQ rosettes following overnight
culture (Tai and Spry, 1978, personal communication).
Human eosinophils and neutrophils were tested for
their rosette forming capacity with human group O Rh +ve
red cells (R-^R^ and R9R2) sensitized with anti-D antibodies.
Neither the eosinophils nor the neutrophils formed rosettes
with these sensitized human red cells. In contrast, the
monocytes tested at the same time formed rosettes with the
same indicator human red cells.
The use of Rh +ve red cells sensitized with anti-D
antibody was reported previously by various workers as an
established technique for the demonstration of the presence
of receptors for human IgG on the human monocyte/macrophage
series (Lo Buglio et al, 1967; Cline and Lehrer, 1968;
Huber £t al, 1969). Later Messner and Jelinek (1970) used
the same method in an attempt to detect IgG receptors on
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human neutrophils. However, with red cells sensitized with
normal anti-D antibody there was no rosette formation by the
neutrophil. In contrast, when they used Ripley anti-D anti¬
body sensitized human red cells, 35% neutrophils formed
rosettes as compared to 48% of the monocyte population. It
is known that the Ripley anti-D differs in several ways from
other conventional anti-D antibodies. For instance, it
reacts with most human rheumatoid factors (Weller and Vaughan,
1956) and it is capable of fixing complement (Harboe et al,
1963). It should be noted, however, that more recently Gupta
et al (1976) reported that they were unable to detect rosette
formation between human eosinophils and human red cells even
when these were sensitized with Ripley anti-D antibody. These
findings are in agreement with the results described in this
study where human red cells sensitized with anti-D antibodies
did not form rosettes with either human eosinophils or neutro¬
phils, although no attempt was made to sensitize the red cells
with Ripley anti-D.
In another series of experiments (Fig. 6) in which an
attempt was made to increase the amount of antibody uptake,
human Rh +ve red cells were treated with the proteolytic
enzyme, papain, before sensitization with anti-D antibodies
and testing for rosette formation with eosinophils and neutro¬
phils. However, these papainized red cells did not form
rosettes with either eosinophils or neutrophils while rosette
formation could be demonstrated with monocytes (Fig. 6). The
papainization of red cells is a well documented method in red
cell serology to enhance antibody/red cell interaction
(Mollison, 1972) especially with antibodies of the Rhesus
blood group. It is thought that the effect of papain
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treatment on the red cell membrane is to increase the amount
of antibody uptake (Masouredis, 1962; Hughes-Jones et al,
1964). It is also possible that the removal of the surface
glycoprotein allows better contact with the antibody molecule.
The rhesus antigen is thought to be part of the lipoprotein
membrane of the red cell (Green, 1972) 'buried* between the
glycoprotein chains bearing other red cell antigens such as
A, B, etc. and this is thought to be one of the reasons why
rhesus antibody molecules do not normally fix complement
although they are of the appropriate IgG subclass (Mollison,
1972). It has also been reported that the action of papain
on the red cell membrane may lead to the movement of the antigen
sites in the membrane which is in a semi-fluid state (Voak et
al, 1974; Romano et al, 1975) and thus the antibody molecules
may form 'clusters* allowing a greater density of activated Fc
receptors to be available. Papainization of Rh +ve red cells
was also used to enhance the K-cell lysis of human red cells by
human monocytes (Holm, 1972) and lymphocytes (Urbaniak, 1978).
Sheep red cells sensitized with rabbit IgM were also
tested for their capacity to form rosettes with human eosino¬
phils and neutrophils at both 0°C and 37°C (Fig. 8). Under
the experimental conditions described there was no significant
rosette formation by either the eosinophil or neutrophil with
x*ct ID j I*CL1D
EA^ and it was, therefore, decided to use these EA^ cells
in the preparation of complement coated intermediates to test
for rosette formation by various complement components.
The presence of a receptor for IgM on certain sub-
populations of human T and B lymphocytes had been reported
over the last few years (Moretta et al, 1975; McConnell
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and Hurd, 1976; Gmelig-Heyling et al, 1976). These
observations were confirmed by Ferrarini et al (1976) who
showed this receptor to be specific for the Fc portion of
IgM. Later Pichler and Knapp (1977) described the
presence of a similar receptor for IgM on chronic leukaemic
cells. Also the presence of a similar receptor on normal
human B lymphocytes after overnight culture was demonstrated
(Ferrarini et al, 1977).
In early experiments performed in the present study
neither the neutrophils nor the eosinophils formed rosettes
with untreated sheep red cells although occasional rosette
formation between some human polymorphonuclear cells and
untreated sheep red cells has been reported previously
(Hsu and Fell, 1974). Furthermore, Sher and Glover (1976)
reported that human eosinophils can form rosettes with
untreated sheep red cells in a similar manner to T lympho¬
cytes. In view of these observations it was decided that
this non-specific binding phenomenon should be closely
evaluated. The rosettes formed between T lymphocytes and
untreated sheep red cells are known to be unstable and are
easily broken with various handling procedures. Several
workers used a variety of test modifications to enhance the
strength of binding between T lymphocytes and sheep red
cells. Weiner et al (1973) reported that neuraminidase
treatment of sheep red cells could enhance rosetting
formation. Also Bentwich et al (1973) could demonstrate
enhanced binding of sheep red cells to T lymphocytes in
the presence of AB serum. The use of both dextran (Brown
et al, 1975) and papainized sheep red cells (Wilson et al, 1975)
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was also reported. In the present study the observation
of Kaplan and Clark (1974), where the treatment of sheep
red cells with the sulphhydryl reagent, AET, was shown to
enhance the non-specific binding between these cells to
human T lymphocytes, was utilized to evaluate the binding
between human eosinophils and neutrophils to AET-treated
sheep red cells. No rosette formation could be demonstrated
with granulocytes, whereas lymphocytes tested at the same time
consistently formed rosettes with the AET-treated red cells
(Fig. 9).
In the present study no experiments were performed
to test for the presence of surface immunoglobulin on human
eosinophils and neutrophils. Gupta et al (1976) were
unable to demonstrate the presence of surface immunoglobulin
on human eosinophils.
Experiments using the rosette technique were performed
to detect the presence of membrane receptors for various
human complement components on human eosinophils and
neutrophils. EAC14 and EAC3 formed rosettes with both
eosinophils and neutrophils (Table V and Figs. 10, 11, 12,
13). Increasing amounts of these components, i.e. C4 and
C3, were associated with a dose-dependent increase in
rosette formation and with lysis on addition of the late
components, suggesting that the percentage of eosinophil
rosettes was directly proportional to the input of C4 and
03 on the indicator sheep red cells (Figs. 14, 15). It
should be emphasized that the amount of 04 used to prepare
the EAC3 intermediates was limited (400 effective molecules)
so that the corresponding EAC14 gave the same percentage of
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rosettes as the untreated red cells. Therefore, the
neutrophil and eosinophil rosettes observed with EAC3
intermediates were not due to C4 and thought to be
entirely C3-dependent. These results are in agreement
with the findings of Gupta et al (1976) who were also able
to demonstrate the presence of these receptors on human
eosinophils and neutrophils. In the present studies, no
experiments were undertaken to study the relationship
between C4 and C3 receptors on human granulocytes. However,
Gupta et al (1976) showed that EAC14 and EAC3b were both
bound by the same eosinophil complement receptor, since
preincubation of eosinophils in either fluid phase C4 or
fluid phase C3c inhibited rosette formation with both types
of intermediates. From similar specificity studies Ross
and Polley (1975) earlier showed that C3b and C4 were bound
by the same receptor on human lymphocytes.
Previously the inability of EAC3d cells to form
rosettes with human neutrophils was reported (Ross et al,
1973; Eden et al, 1973). However, in the present study
EAC3d cells, prepared by treating EAC3b cells with human C3b
inactivator, formed rosettes with both eosinophils and
neutrophils. These EAC3d cells, unlike the EAC3b cells,
were immune adherence negative, resistant to lysis by the
addition of C5-C9 and gave a stronger agglutination with
monospecific anti-C3d than did the EAC3b cells, but they
were not tested for rosette formation with Daudi lymphoid
cells, which carry only receptors for C3d (Dierich et al,
1974b; Theofilopoulos et al, 1974). It should be
emphasized here that in the present study, the term *C3d
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receptors' refers only to those receptors which will react
with the C3b inactivator-treated EAC3b which are no longer
immune adherence positive and which cannot be lysed by the
addition of C5-C9. It is not intended to include the
various complex molecular mechanisms which occur as a
result of the action of the C3b inactivator on the C3b
molecule (Harrison and Lachmann, 1978). For this reason
more recent reports have referred to CRg (complement
receptor type 2) instead of C3d receptors (Ross et al, 1978).
The differences between the results presented here and those
of earlier reports (Ross et al, 1973; Eden et al, 1973) may
be explained by differences in technology. Indeed, more
recently Ross et al (1978) have also demonstrated the
presence of receptors for C3d receptors (CI^ on human
neutrophils. They have taken advantage of the finding
that the neutrophil cell density increases with maturation
and so by using density gradient centrifugation they were
able to separate various fractions of neutrophils. These
different neutrophil fractions were thought to represent
different individual cell maturation stages. The presence
of C3d receptors was found to be associated with the less
mature cells and it was suggested that this receptor may
be lost after full cellular maturation.
Rosette formation by neutrophils and eosinophils with
EAC14 was inhibited by functionally pure human C2 which was
free of C3b inactivator (Table I). Although it was
previously reported that C2 did not inhibit EAC14 immune
adherence (Cooper, 1975), it should be mentioned that in
the present study the inhibition of EAC14 rosette formation
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was performed at 0°C to minimize C2 decay. By allowing
C2 to decay at a higher temperature, rosette formation by
EAC14 could be restored (Tables I, II). These findings
suggest that C4-haemolytic and granulocyte-binding sites
are likely to be closely related.
The functional significance of C4 and C3b receptors
on various phagocytes may be difficult to explain in
relation to the presence of C3b inactivator that renders
EAC14b and EAC3b complexes non-reactive with the immune
adherence receptors. Antigen-antibody complexes in plasma
fix C4b and C3b which are rapidly cleaved by plasma C3b
inactivator into the respective c and d fragments (Cooper,
1975; Ruddy and Austen, 1971). The C4b cleavage products,
C4c and C4d, are believed to be non-reactive with complement
receptors (Bokisch and Sobel, 1974), while the complex-bound
C3b cleavage product, C3d, only has activity with C3d
receptors. In vivo, however, C4b sites on antigen-antibody
complexes may be partially protected from C3b inactivator
action by formation either of a short-lived complex with C2
(Cooper, 1975) or with the low molecular weight C4b binding
protein (Nagasawa and Stroud, 1978). This may help to
preserve C4b sites long enough to allow binding of antigen-
antibody complexes to the immune adherence (C4 and C3b)
receptor-bearing phagocyte. There is also a similar
complexity in the in vivo reactions involving bound C3b.
It is known that when the antigen-antibody complexes are
sheep red cells (EAC), the cell-bound C3b cleavage product,
C3d, has little opsonic activity (Gigli and Nelson, 1968;
Stossel et al, 1975; Ehlenberger and Nussenzweig, 1977).
However, under normal circumstances in vivo C3-coated
190
bacteria and yeast are usually phagocytosed whilst
erythrocyte target cells are likely to be handled instead
by lysis with natural antibody and complement. It was
shown also that yeast cell wall-derived zymosan surface
membranes differ from sheep red cell membranes in that
alternate pathway-derived C3b is bound in such a way that
it is relatively resistant to C3b inactivator cleavage
(Fearon and Austen, 1977). Therefore, it seems that with
both yeast and bacteria C3b can act as an effective opsonin
despite the presence of C3b inactivator.
The relationship between granulocyte complement
receptors and eosinophilia was studied. There was a
significant decrease in the percentage of eosinophil
rosettes with EAC14 and EAC3b in patients with eosinophilia
(Fig. 7). This may possibly be due to the presence of
smaller numbers of complement receptors on immature
eosinophils which appear more commonly in the peripheral
blood of these patients as a result of the stimulation of
their production and release from the bone marrow. This
concept is supported by the work of Gupta (1977), who
studied the sequence of appearance of surface receptors
for complement and immunoglobulin on human lymphocytes,
and showed that the complement receptors were the last
to appear during lymphocyte maturation. In addition,
Rabellino and Metcalf (1975) were unable to demonstrate
receptors for C3 on mouse eosinophil colony cells grown
in vitro, whereas in the same study IgG receptors were
demonstrated. This is in agreement with the present
study in which there was no difference between eosinophils
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rosetting with EA^ in patients with eosinophilia when
compared to controls.
There was no apparent association between the per¬
centage of eosinophil or neutrophil rosettes with EAC14 or
EAC3b and the degree of eosinophilia. Also there was no
association between the percentage of EAC14 and EAC3b rosette
formation and the disease states.
These results described in the present study are in
agreement with the previously described surface receptors
on human monocytes (Huber and Fudenberg, 1968; Huber et al,
1968) in that, like monocytes, human granulocytes bear
receptors for IgG, C4, C3b and C3d. This suggests that
there are similarities in terms of recognition of opsonized
particles by all circulating phagocytic cells.
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2.0 ENHANCEMENT OF HUMAN EOSINOPHIL COMPLEMENT RECEPTORS
BY PHARMACOLOGICAL MEDIATORS
Using the rosette technique it was shown that the
expression of the human eosinophil complement receptors can
be enhanced by agents previously recognised to be selectively
chemotactic for human eosinophils. The actual mechanisms
involved in the increased receptor expression are as yet
unclear. The elucidation of such mechanisms is made more
difficult by the fact that little is known about the
physiochemical characteristics or the arrangement of the
complement receptors on the cell membrane.
It should be mentioned that during this chapter the
various eosinophilotactic agents, i.e. the ECF-A tetra-
peptides, histamine and imidazoleacetic acid, were
consistently referred to as being chemotactic only in the
sense that they cause the eosinophil to migrate in vitro
towards a gradient across a micropore filter. Further
studies are needed where all these agents are examined,
either alone or in combination, using the ,chequerboardt
titration method so as to distinguish true chemotaxis from
chemokinesis (Zigmond and Hirsch, 1973; Keller et aT, 1977).
Also, the relationship between chemotaxis, chemokinesis and
complement receptor enhancement may need to be defined.
The ECF-A peptides and histamine were apparently
unable to enhance neutrophil or monocyte complement
receptors. This demonstrates further the more intimate
relationship between these anaphylaxis-related agents and
the eosinophil leucocyte. It was not possible for the
effect of the ECF-A peptides and histamine on neutrophils
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and monocytes to be revealed when the amount of C3 input
on the indicator red cells was reduced, since in experiments
where the C3 input was adjusted to give less than half the
number of rosetting cells (i.e. 1000 effective molecules)
there was no increase in the percentage of the rosetting
neutrophils or monocytes following the incubation with
either the peptides or histamine (Table VI).
The ECF-A peptides, histamine and imidazoleacetic
acid had no effect on the number of EAQ rosettes formed
with any of the leucocytes tested. The apparent inability
of these agents to enhance receptors for IgG on the
eosinophil may have been due to the slight differences in
the experimental conditions since rosette formation with
IgG-coated red cells was performed at 0°C whereas 37°C was
used as the optimal temperature for EAC rosette detection.
On the other hand, C3d receptors (which were also identified
at 37°C) were unaltered by these same pharmacological agents.
Therefore, the difference in the incubation conditions seems
unlikely to explain the inability of the mediators to influence
eosinophil IgG receptors. It should be stated that at 37°C,
in contrast to 0°C, there was considerable phagocytosis of
i*sib
EA£. by granulocytes and it was, therefore, impractical to
1*3.13
perform the EA^ receptor enhancement studies at a higher
temperature. The use of more sensitive techniques, e.g.
immunofluorescence, might be more useful in studying the
1*3,13
possible effects of these agents on enhancement of EA„Lr
receptors.
In the studies described here optimal receptor
enhancement was achieved during a relatively short incubation
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period (60 min) which would make it rather unlikely that new
receptors were generated during this time. The treatment
of eosinophils by these agents may have unmasked previously
hidden receptor sites or facilitated some form of externali-
zation. For instance, complement receptors may behave like
those for low density lipoprotein on human fibroblasts, which
are believed to have a continuous ordered motion around and
through the cell (Anderson et al, 1977). Another possibility
is that the pharmacological agents may lead to Enfolding*
of the cell membrane to expose more receptor sites which
would have otherwise remained inaccessible. Alternatively,
complement receptors may be composed of subunits which,
following treatment with agents that can cause cell migration,
lead to their association with consequent binding of more
indicator cells. Some of the possible mechanisms involved
in receptor enhancement are represented diagrammatically in
Fig. 30. One further explanation may be dependent, not on
gross movements of the receptors or their subunits, but on
an increase in the binding affinity or increased 'stickiness*
of that part of the cell membrane which adheres to complement-
bearing particles.
Although the use of the rosette method for studying
cell surface markers is well established, a major dis¬
advantage, which applies particularly to the present study,
is the difficulty in measuring the degree of binding between
the cell membrane and individual indicator erythrocytes.
It was found that eosinophils treated with the ECF-A
peptides, histamine or imidazoleacetic acid not only
increased the percentage of cells bearing three or more
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Fig. 30
Diagrammatic representation of some of the possible
mechanisms of receptor enhancement.
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red cells, but the red cell binding appeared far stronger
than that observed in the untreated controls. From these
observations it became evident that the rosette technique
was not the ideal method and that more detailed studies in
which other more sensitive techniques, which will facilitate
measurements of the binding affinity, are required for the
appreciation of the full extent of the receptor enhancement
as a new biological phenomenon.
It was further shown that 'non-eosinophilotactic8
mediators of anaphylaxis, e.g. bradykinin, prostaglandins
(PGE^, E2 and F2a) and 5-hydroxytryptamine, and other agents
closely related chemically to histamine, but chemotactically
inactive such as histidine and the major catabolites of
histamine (1,4-MeHm, N-AcHm and 1,4-MeImAA) when tested for
C3b receptor enhancement on eosinophils, were without effect.
This finding suggests that the enhancement of complement
receptors is a chemotaxis-related phenomenon. It is now
possible to say that the complement receptor enhancement
may be a general biological phenomenon applicable to all
those cells which both respond in chemotaxis and bear
complement receptors, i.e. agents which promote cell
migration can also enhance complement receptors. For
example, the synthetic N-formylmethionyl peptide, F-Met-
Leu-Phe, previously shown to be chemotactic for the
neutrophil (Schiffman et al, 1975) enhanced neutrophil C3b
receptors (Salter, D.M., unpublished observation).
Similarly, agents having a recognised chemotactic activity
for mononuclear phagocytes including casein (Keller and
Sorkin, 1967) and 8lymphokines* (Snyderman et al, 1972)
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(prepared from lymphocytes incubated with phytohaemagglutinin)
enhanced C3b receptors on monocytes (Glass, E.J., unpublished
observations).
Experiments performed to study the effect of various
combinations of the ECF-A peptides and histamine on C3b
receptor enhancement gave quite different results to similar
studies previously reported for eosinophil chemotaxis
(Turnbull et al, 1977). Whereas, with chemotaxis, mixing
of the agents seemed to abrogate the response (Turnbull
et al, 1977), with receptor enhancement there was neither
abrogation, addition or synergism when various mixtures of
the mediators were tested. It is possible that the
previously reported mixing experiments (Turnbull et al, 1977)
may have induced a form of chemotactic *deactivation * under
the experimental conditions used, a phenomenon which may not
apply to receptor enhancement by the ECF-A tetrapeptides or
histamine.
It was observed during the course of these receptor
enhancement studies that there were two patterns of response
to histamine in terms of its effect on eosinophil C3b receptors
(.not shown in the results). In one type of response,
eosinophils showed marked receptor enhancement similar to
the response of the ECF-A peptide, whereas in the other type
histamine produced a much lower degree of enhancement. It
was previously reported that there were alterations in
various disease states in terms of the eosinophil chemotactic
response to histamine and the ECF-A peptides (Bryant et al,
1977). In the present study no attempt has been made to
relate the degree of receptor enhancement to various disease
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states. However, an altered response in disease similar
to that previously reported in relation to eosinophil
chemotaxis may also apply to the receptor enhancement
phenomenon.
The studies described here indicate that an important
biological function of chemotactic agents may be their
capacity to render leucocyte complement receptors more freely
available, thereby increasing the magnitude of adhesion to
opsonized particles. This raises the possibility that
leucocytes are primed for adhesion process prior to their
actual attachment. Furthermore, eosinophil complement
receptor enhancement represents a previously unrecognised
biological activity for the ECF-A tetrapeptides, histamine
and imidazoleacetic acid. This activity may be more
relevant to the role of eosinophils as cytotoxic cells
against the larvae of certain helminths where the IgE-
mediated release of chemical mediators is well recognised.
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3.0 THE PARTICIPATION OF ANTIBODY AND/OR COMPLEMENT
IN EOSINOPHIL-DEPENDENT KILLING OF SCHISTOSOMULA OF
SCHISTOSOMA MANSQNI
In the experiments described in section IV (see
Results) a direct visual assay for helminth damage was
used. In this assay, schistosomula killed by adherent
leucocytes were easily recognised and quantitated by their
distinctive appearance. The direct visual assay has the
advantage of being relatively simple and inexpensive as
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compared, for instance, with the chromium release method
and was found, in the author's hands, to compare favourably
with the latter in terms of sensitivity and reproducibility.
However, one disadvantage is that it is rather laborious and
time-consuming especially if many wells are to be counted.
Previously in similar studies (Butterworth et al, 1974;
Butterworth ejt al, 1975; Butterworth £t al, 1977a, b) the
o 1
chromium release assay was used as the method for
measuring damage of the schistosomula and the results were
essentially similar to those presented here. Indeed,
recently Mackenzie et al (1977) have shown that by using
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both methods, i.e. the direct visual assay and the chromium
release assay, the schistosomula damage proceeded in parallel.
In the present studies three experimental systems were
used, i.e. (a) 'antibody alone', (b) 'complement alone',
where fresh normal human serum was used as a source of
complement through the activation of the alternate complement
pathway by the tegument of the schistosomula, and (c) the
combination of antibody and complement.
With the 'Ab alone' system the percentage killing of
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schistosomula by human leucocytes found in this study was
in agreement with studies of Butterworth et al (1975) and
Butterworth et al (1977a, b) who found that killing
(approximately two and one half times) was significantly
greater than the appropriate control. These percentages
were significantly higher than the control (Table VII).
With ®complement alone® the results are also in agreement
with a previous study in which schistosomula coated with
rat C3 were shown to be more susceptible to damage by rat
eosinophils than those coated with IgG (Ramalho-Pinto et al,
1978). However, in the present study using human leucocytes
and complement, neutrophils and mononuclear cells were also
studied in addition to the eosinophil. With all these cell
types complement-coated schistosomula were more susceptible
to killing than schistosomula coated with antibody alone.
Unlike the previous study in the rat (Ramalho-Pinto et al,
1978) the degree of killing with fC alone® in the present
study was consistently less than that previously reported
with the rat eosinophil and complement, i.e. 52.9% as
compared to approximately 90%. This discrepancy may be
due to the fact that in the previous study in the rat
(Ramalho-Pinto ejt al, 1978) schistosomula were used only
3 hr after transformation from cercariae whereas in the
present study they were used after approximately 24 hr.
In this respect it is worth noting that Ramalho-Pinto et al
(1978) showed previously that complement-dependent adherence
in 5-day-old schistosomula was negative. Alternatively,
the results may simply reflect the species difference
between the two studies. '
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The combination of antibody and complement was studied
since it might be more relevant to the in vivo situation in
resistance to reinfection. This combination, i.e. ?Ab + Cv,
was found to be the most efficient system with both cell
types (granulocytes and mononuclear cells) in terms of their
capacity to cause schistosomula damage. A similar system
was previously described by Dean et al^ who found that
schistosomula coated by rat (Dean et al, 1974) and guinea
pig (Dean et aJ, 1975) antibody and complement were
susceptible to damage by neutrophils. Under the conditions
described in the present study schistosomula killing by
*Ab + C* in the absence of leucocytes was minimal (Table VII),
which also confirmed the previous findings of Dean et al
(1974).
With all three experimental systems used the mono¬
nuclear cells (which contained less than 3% granulocytes)
were relatively less effective than the granulocyte
suspensions in terms of their capacitj/ to mediate schisto¬
somula damage. In the present study no attempts were made
to determine whether individual cell types which comprised
the mononuclear leucocytes, i.e. subpopulations of lymphocytes
or monocytes, were more or less effective on a cell to cell
basis, when compared to eosinophils or neutrophils.
Nevertheless, in this respect, the finding that mononuclear
cells can mediate schistosomula damage is in agreement with
the findings of Capron et al (1975) who described schistosomula
killing by rat macrophages. However, these workers found
that killing by macrophages was dependent on IgE antibody.
In the experiments described in this study the participation
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of IgE was virtually excluded since all the anti-schistosomula
sera used as antibody source were heat-inactivated for 1 hr
at 56°C. Furthermore, evidence was provided that the
mediating antibody class was IgG.
In the 'Ab alone* system killing was related to the
concentration of the anti-schistosomula serum and with
'C alone* and 'Ab + C* to the amount of complement (Fig. 24),
although it might be argued that it is not valid to compare
schistosomula coated with (1) whole undiluted fresh serum as
a source of complement with (2) undiluted anti-schistosomula
serum in terms of susceptibility to killing by various
leucocytes. For instance, the affinity of the antibody in
the 'Ab alone' system may not have been sufficient to allow
full expression of leucocyte-mediated schistosomula damage.
However, this was unlikely since the 17 sera tested from
patients with schistosomiasis, all gave killing within a
fairly narrow range (25-45%). Furthermore, the serum
samples were obtained from patients at different stages of
the natural history of the disease indicating that they
probably represented a broad spectrum of the anti-schistosomula
antibody response. These data, therefore, taken together
with the previous findings in the rat (Ramalho-Pinto et al,
1978) suggest that complement-coated schistosomula are
particularly susceptible to damage by various leucocytes.
During the course of the present study no attempts
were made to study quantitatively the degree of leucocyte
adherence to schistosomula in relation to killing. However,
it was consistently observed that cell adherence to antibody-
coated schistosomula could occur without appreciable
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schistosomula damage. In contrast, with the *C alone1 and
*Ab + C* systems, adherence and damage were directly related.
In a previous study, using the rat cells, where adherence and
killing were observed in parallel it was found that antibody-
mediated cell adherence can occur without appreciable
schistosomula damage (Ramalho-Pinto et al, 1978). Further¬
more, in a more recent ultrastructural study (McLaren et al,
1978) it was shown that adherence of rat eosinophils to
schistosomula coated with complement resulted in an earlier
and more severe damage than antibody-dependent destruction.
Experiments were performed to study the capacity of
schistosomula to activate the human complement system by
the alternate pathway. In these studies the main evidence
was obtained in experiments using C2-deficient serum
(Table VIII) although the possibility that normal human
serum may contain small amounts of natural anti-schistosomula
antibody was not fully excluded since with normal serum
there was a minimal fluorescence with anti-C4 (Table VIII).
Previously Ramalho-Pinto et al (1978) showed that
schistosomula can activate the alternate pathway of the
rat complement system. The activation of the alternate
pathway of complement by cercarial glycoprotein has also
been reported (Machado et al, 1975). It seems likely that,
with schistosomula, surface glycoproteins are also involved
in complement activation by the alternate pathway. With
fluorescent-labelled anti-C3, immunofluorescence was
observed to be evenly distributed over the entire surface
of the schistosomulum (Plate IX) indicating that the
activating principle is an integral part of the tegument.
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Furthermore, experiments were performed where senstiized
schistosomula were coated by the sequential addition of
the purified human complement components CI, C4, C2 and C3.
Using this approach it was shown that susceptibility to
damage by granulocytes of the schistosomula coated with
antibody could be augmented with the purified classical
pathway components and to be dependent on the input of C3
(Fig. 26). The presence of C3 on these schistosomula was
also detected by immunofluorescence (Table VIII). With
the addition of the purified complement components, as
well as with *C alone* and *Ab + C' systems, the adherence
and damage were presumably mediated via C3b and the
appropriate receptors on the eosinophils and neutrophils,
although these cell types were also shown to bear receptors
for C4 and C3d. At the present time the role of these
receptors in mediating adherence and possibly damage is
not known. However, it is unlikely that the adherence
and killing in experiments using the purified components
was mediated via C3d and its appropriate receptors since
the C3b inactivator was not present in the reaction
mixtures.
Experiments were performed to determine the antibody
class mediating the damage in the *Ab alone* and 'Ab + Cr
systems. This was achieved by using purified IgG, free
from detectable IgM and IgA. There was very little
difference between whole anti-schistosomula serum and the
purified IgG fraction in terms of their capacity to mediate
granulocyte-dependent killing in those two systems (Fig. 25).
However, a serum fraction free of IgG and containing comparable
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amounts of IgM and IgA to those contained in the whole serum
had no killing effect. This finding confirmed previous
observations by Butterworth et al (1977b) who found that
antibody-dependent schistosomula damage was mediated by IgG.
Since it became evident that both neutrophils and
eosinophils can mediate schistosomula damage in all three
experimental systems, experiments were designed to
investigate the relative efficiency of eosinophils and
neutrophils in schistosomula killing in the three experi¬
mental systems. For these studies cells from healthy
donors were used because it was previously reported that
eosinophils from eosinophilic patients with schistosomiasis
were relatively ineffective in antibody-dependent cytotoxicity
(Butterworth et al, 1975). Preferential killing of schisto¬
somula by one cell type can be demonstrated by testing a
number of cell suspensions, prepared from the same donor, in
which the percentage of this cell type was varied whilst
keeping the total cell count constant. Experiments performed
using this approach, with seven different donors, showed
that increasing the percentage of the eosinophils in the
cell suspension resulted in increased killing of schistosomula
but only in systems containing complement either alone, or
in combination with antibody (Fig. 29). However, with *Ab
alone * there was no alteration in the schistosomula killing
following the increase in the eosinophil percentage and it
appeared that both eosinophils and neutrophils were equally
effective in mediating schistosomula killing. These
findings, with rAb alone', differed from those of Butterworth
et al (1975) and Butterworth et al (1977a) who reported that
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eosinophils were the only human blood leucocytes capable
of mediating appreciable antibody-dependent killing of
schistosomula. These workers prepared schistosomula by
cercarial penetration of skin whereas organisms transformed
artificially by mechanical procedures were used here.
However, this is unlikely to explain these differences since
there is no evidence that schistosomula transformed artifi-
ficially by mechanical separation of the tails differ from
schistosomula recovered after cercarial penetration of
isolated skin. Immunofluorescence studies indicated that
both types of schistosomula could bind serum from mice
immune to Schistosoma mansoni and both had a comparable
infectivity when injected intravenously in mice (Brink et al,
1977). In the experiments described here a different assay
was used from that used by Butterworth et al (1975), i.e.
killing was measured by a direct visual assay, whereas
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Butterworth et al (1975) used chromium release as a
measure for schistosomula damage. It is also unlikely
that these different assay systems may explain the dis¬
crepancies since using both methods schistosomula damage
has been shown to proceed in parallel (Mackenzie et al, 1977).
The supporting media used in the present study were RPMI-1640
and medium 199, in contrast to Eagle's minimal essential
medium supplemented with 10% heat-inactivated foetal calf
serum as used by Butterworth et al (1975). The most likely
reason for the difference in the findings with respect to
the 'Ab alone' system is the difference in the experimental
design, rather than the difference in the culture conditions
and assay. Butterworth et al (1977a) compared the degree of
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schistosomula damage by eosinophil-rich suspensions from
seven individuals and in six of these dose-response curves
were obtained by varying the effector cell/target ratio.
There are difficulties in demonstrating a specific property
for the eosinophil, or any other cell type, using this approach
since it assumes that preparations from different individuals
containing the same percentage of the cells under study are
equally effective. Because of variability of cells obtained
from different donors in terms of biological efficiency, this
assumption might not always be valid. Therefore, it is
important to keep the effector cell/target ratio constant
and to 'dose-response* by increasing the concentrations of
eosinophils using several suspensions from the same donor,
thereby largely overcoming the difficulties of variations
between different individuals.
It was previously shown by Butterworth et al (1975)
that the use of monospecific anti-eosinophil serum abrogated
antibody-dependent leucocyte damage to schistosomula. In
the present study no experiments were performed using mono¬
specific anti-eosinophil serum.
Although preferential damage by eosinophils could be
demonstrated in the two systems incorporating complement,
it was evident that the neutrophil was also an effective
cytotoxic cell (Fig. 29). For instance, with the highly
neutrophil-rich suspensions (approximately 97%) killing with
*C alone' was between 27 and 40% and between 37 and 50% for
*Ab + C*. If schistosomula damage by the neutrophil-rich
suspensions was entirely due to contamination by eosinophils
then this would imply that, from the results shown in Fig. 29,
208
a ratio of 120-400 eosinophils per schistosomulum was
sufficient to cause appreciable damage. This is extremely
unlikely since it is known from the individual eosinophil
counts of the granulocyte suspensions in experiments
performed to determine the effector cell/target ratio used
in the present studies (Fig. 27) that a ratio of 400:1 was
insufficient to cause schistosomula damage which was greater
than that caused by controls.
With TC alone' and 'Ab + C' the effect of increasing
the eosinophil percentage in the granulocyte preparations
seemed to plateau between approximately 20 and 35%
eosinophils (Fig. 29). The reasons for this 'plateauing'
effect are unclear at the present time although this may
be a reflection of the maximal degree of killing possible
in this in vitro assay.
In the present studies no attempts were made to study
the exact mechanisms of schistosomula damage by human
leucocytes in the three experimental systems. Previously
the reactions between human eosinophils and schistosomula
in the 'Ab alone' system were examined by phase contrast
and electron microscopy (Butterworth, A.E., personal
communication). It was shown that the reaction was
initially characterized by a tight adherence between the
eosinophil and the schistosomulum, a feature which was not
seen in control preparations. This stage was followed by
eosinophil degranulation and by the appearance of an
electron-dense deposit on the surface of the worm. Some
eosinophils might then withdraw from the surface, while
others might be seen in the process of phagocytosing
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fragments of the extensively damaged schistosomula. While
studying the ultrastructural changes occurring between rat
eosinophils adhering to schistosomula in the presence of rat
immune serum, McLaren et al (1977) showed that the initial
response of the rat eosinophil was degranulation leading to
the formation of large cytoplasmic vacuoles. Peroxidase
was discharged into these vacuoles as a consequence of
degranulation. Eventually the vacuoles became connected
to the adherent basal membrane of the eosinophil, and
peroxidase was directly secreted on to the surface of the
worm. However, these workers were unable to detect any
morphological evidence to suggest that these particular
reactions following eosinophil adherence could affect the
integrity of the schistosomulum surface. More recently,
ultrastructural evidence for both complement and antibody-
dependent damage to schistosomula by rat eosinophils was
provided by McLaren ejb al (1978) who observed the
appearance of focal lesions in the tegument of the schisto¬
somula following the secretion of enzymes by the eosinophils
on to the parasite surface. The cells were observed within
these lesions and later between the basal plasma membrane of
the tegument and the underlying interstitial material. It
was, therefore, suggested that the eosinophils are responsible
for prising the tegument away from the body of the worm and
the detached tegument would show evidence for further
degradation. It was also observed that the complement-
dependent adherence of rat eosinophils resulted in earlier
and more severe damage to schistosomula than when adherence
occurs through IgG (Fc) receptors. In the same study, rat
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eosinophils were shown to adhere to C3-coated Sepharose
beads, but evidence of enzyme secretion was only obtained
when the target was a schistosomulum.
It is possible that the adherence by human eosinophils
to complement-coated schistosomula may lead to a series of
events and membrane changes, similar to those described
with the rat eosinophil, which will ultimately cause damage
of the parasite. However, this is yet to be substantiated.
In any case, it seems, from the results described in the
present study with the human eosinophil together with those
previously described in the rat eosinophil (McLaren et al,
1978), that eosinophil adherence to complement-coated
schistosomula will generate a more effective mechanism




4.0 CONCLUDING COMMENTS AND SUGGESTIONS FOR FUTURE STUDIES
The aims of the present studies were primarily to look
for the presence of surface markers for immunoglobulins and
complement on human eosinophils, to study the ways in which
the expression of these receptors might be modulated, and
finally to investigate the role that the human eosinophil
might play via its membrane surface receptors in schisto-
somula killing. Eosinophils used in this study were usually
obtained from patients with eosinophilia although in certain
experiments cells from healthy controls were also studied.
It was not possible on any occasion to obtain a 100% pure
eosinophil preparation, and neutrophils were the usual
contaminating cell. However, their unwanted presence was
useful, in some ways, since it provided both control and
comparative measurements.
The presence of receptors for IgG on both eosinophils
and neutrophils was confirmed. No attempts were made to
define the subclasses of IgG involved. Also the presence
of receptors for various human complement components were
studied. Human eosinophils and neutrophils were shown to
bear receptors for C4, C3b and C3d. The presence of C4 and
C3b receptors was previously reported by Gupta et al (1976).
The inability of human neutrophils to form rosettes with
EAC3d cells was reported earlier (Ross et aT, 1973; Eden
et al, 1973). However, in a recent report Ross et al^ (1978)
have demonstrated the presence of C3d receptors on less mature
neutrophils and they claimed that this receptor is lost during
full cellular maturation.
The results presented in this study are consistent with
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the previous findings on surface receptors on human monocytes
(Huber and Fudenberg, 1968; Huber et al, 1968) in that, like
other phagocytes, the eosinophils and neutrophils bear
receptors for C4, C3b and C3d. Phagocytosis by the
eosinophils is considered to be relatively less important
than that by monocytes or neutrophils and the relative
paucity of the eosinophil receptors may explain its poor
phagocytic response. Eosinophils are now believed to be
involved in certain major processes in the body, i.e. they
may act as a cytotoxic-killer cell against certain helminths
and they may have a homeostatic effect in immediate hyper¬
sensitivity reactions. Both these roles presumably require
an effective recognition mechanism enabling contact between
eosinophils and target cells which in turn may depend on
immunoglobulin and/or complement receptors.
The ECF-A tetrapeptides, histamine and imidazoleacetic
acid were shown to enhance the expression of complement (C4
and C3b) receptors on human eosinophils. This finding
represents a previously unrecognised important biological
activity for mediators of anaphylaxis known previously to
be selectively chemotactic for eosinophils. Furthermore,
the role of other chemotactic factors (casein and lymphokines;
and F-Met-Leu-Phe) in mediating complement receptor enhancement
on monocytes and neutrophils was demonstrated (Glass, E.J. and
Salter, D.M., unpublished observation). These observations
on the three cell types indicate that complement receptor
enhancement by chemotactic factors may be an important
general biological phenomenon related to all cells which
respond in chemotaxis and bear complement receptors.
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The exact way in which these chemotactic agents may
affect the cell membrane receptors is unclear at the present
time although various possible mechanisms are suggested
(Fig. 30). However, more detailed studies are needed in
which the whole phenomenon of complement receptor enhance¬
ment is studied at the membrane molecular level. Such
studies may clarify the way in which chemotactic agents
trigger the cell membrane to respond by receptor enhance¬
ment. Such elucidation will possibly be made more
difficult by the fact that both the physiochemical nature
and the arrangements of the complement receptors on the
cell membrane are far from being clear at the present time.
In all the studies described in this thesis in relation
to complement receptor enhancement no attempts were made to
study the relevance of the enhancement, as a phenomenon, to
various other recognised cellular processes, e.g. phagocytosis,
release of lysozomal enzymes and K-cell cytotoxicity. It
is possible that the enhancement of complement receptors may
be one way through which other cellular mechanisms, which
are dependent in one way or another upon the presence of
complement receptors, are also enhanced.
It was observed during the course of the enhancement
studies that the response to histamine was not consistent
and there was a preliminary suggestion that this altered
response to histamine may be related to different clinical
conditions. These preliminary findings must be further
substantiated by carrying our more detailed studies in which
the degree of receptor enhancement is related to various
disease states.
Like other effects of histamine, complement receptor
enhancement may be mediated through various histamine
receptors, HI- and H2-receptors. The study of these
mechanisms is now possible using histamine antagonists
which are known to be specific for one type of histamine
receptor, i.e. either HI or H2 antagonists. Preliminary
experiments performed (not shown in the results) indicated
that complement receptor enhancement may be an HI effect
since it was specifically inhibited by HI antagonists only.
However, these data are far from complete and more
experimental work is needed in this area.
Experiments in which the effect of crude anaphylactic
diffusates was studied for receptor enhancement activity,
showed clearly that the diffusate could cause C3b receptor
enhancement which was demonstrable in a dose-dependent
fashion. This effect may be due not only to histamine
and ECF-A tetrapeptides, but also to other high molecular
fractions present in the anaphylactic diffusate. This
possibility can be resolved by testing various fractions
obtained from chromatographic purifications of the crude
diffusate.
The studies on complement receptor enhancement will
not be complete until the roles of various metabolic
inhibitors in relation to this phenomenon are tested.
Studies were performed to investigate the capacity of
various human leucocytes to mediate killing of schistosomula
of Schistosoma mansoni in the presence of antibody alone,
complement alone or in combination with antibody. The
results of these studies confirmed the previous findings
215
of Butterworth ejb al (1975) who showed that human eosinophils
could mediate damage to schistosomula coated with antibody.
However, in the present study neutrophils were found to be
equally effective as killer cells against antibody-coated
schistosomula.
For the first time the human complement system was
shown to be involved in damage of schistosomula by human
leucocytes as was the ability of schistosomula to activate
the alternate pathway of this system. These findings
confirmed the previously reported data in which the rat
eosinophil was shown to mediate killing of complement-
coated schistosomula (Ramalho-Pinto et al, 1978). The
combination of antibody and complement provided a more
efficient killing mechanism which is presumably more
relevant to the in vivo situation. The role of this system
was further demonstrated by coating of the sensitized
schistosomula by the purified human complement components
of the classical pathway. A significant increase in the
schistosomula damage was shown to be dependent upon the
input of purified C3 (Fig. 26). The role of C4 and C3d
in mediating 04 or C3d-coated schistosomula will need
further investigation.
Preferential damage of schistosomula by human
eosinophils could only be demonstrated in the presence of
complement either alone or in combination with antibody
(Fig. 29). The relation between the eosinophil leucocyte
and the complement system with respect to schistosomula
damage is unclear at the present time. It was previously
suggested that the activation of the complement system at
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the schistosomula surface may generate certain eosinophil
chemotactic factors, probably C3a, C5a and C567 (Ramalho-
Pinto et al, 1978). However, these complement-derived
eosinophil chemotactic factors were also shown to be
chemotactic for neutrophils as well (Ward, 1971). It was
not possible for Ramalho-Pinto et aJ (1978) to study the
role of neutrophils in compelemt-mediated damage of
schistosomula since their rat eosinophil cell suspensions
(obtained from peritoneal washings) contained only macro¬
phages as contaminating cells. Therefore, preferential
killing of complement-coated schistosomula by human
eosinophils described in the present study is unlikely to
be due to the generation of complement-derived eosinophil
chemotactic factors. The most likely explanation is that
adherence of eosinophils to complement-coated schistosomula
may cause the cell to release cytotoxic enzymes which are
quantitatively or qualitatively different from those released
after the antibody-mediated adherence.
Previously the role of rat macrophages in mediating
schistosomula damage was demonstrated and was shown to be
dependent on IgE antibody (Capron et al, 1975). Again rat
macrophages were shown to play a role during the final stages
of rat eosinophil-mediated damage of schistosomula. These
macrophages were shown to ingest both eosinophils which
release their cytotoxic enzymes and the disrupted tegument
of dead schistosomula (McLaren et al, 1978). In the present
study human mononuclear cells were shown to mediate signifi¬
cant schistosomula damage in the presence of antibody and/or
complement. No experiments were performed where various
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subpopulations of the mononuclear cells were tested
separately for their capacity to kill schistosomula. Such
studies are important and may now be facilitated by the
development of better techniques for separation of various
mononuclear subpopulations.
The observation that the ECF-A tetrapeptides and
histamine can enhance eosinophil complement receptors may
be potentially relevant to helminth destruction in vivo.
The IgE-mediated release of chemical mediators of anaphylaxis
is well established during the early stages of contact
between the host and the parasite. Therefore, one may
speculate that the release of these mediators may cause
eosinophils, with their enhanced complement receptors, to
migrate to the site of the skin penetration where they are
more efficient as killer cells (Fig. 31). Indeed, it has
recently been shown that there was a significantly greater
number of eosinophils at the site of cercarial challenge
in the ears of immune mice (Sher, A., personal communication).
Also the role of these mediators in enhancing the parasiti-
cidal effect of rat eosinophils was recently demonstrated
when the incubation of these cells with supernatants from
degranulated mast cells, which presumably contained ECF-A
and histamine, was shown to increase significantly the
capacity of eosinophils to mediate schistosomula damage
(Capron, A., personal communication). All these interesting
observations will need further experimental substantiation.
In the studies described in this thesis peripheral
blood eosinophils were the usual source of eosinophils.





















Diagrammatic representation of the possible mechanisms
involved in helminth destruction by eosinophils.
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not be the true representation of the whole spectrum of the
various eosinophil leucocyte reactions since the majority
of these cells occur in the tissues rather than in the
peripheral blood. However, until a convenient technique
for the separation of human tissue eosinophils is available,
the peripheral blood will remain the most reliable source
for studies on human eosinophils.
Finally, all the studies described in this thesis were
undertaken in an attempt to answer some questions in relation
to the in vivo role of this unique cell. In this respect,
the results presented here provided a number of useful
insights although many more questions still need to be
answered.
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